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Abstract 
Metformin is an anti-hyperglycaemic agent widely prescribed for type 2 diabetes 
(T2D). Despite decades of clinical use, its exact pharmacological mechanism(s) is 
yet to be definitively determined. Accumulative data have shown its mild 
inhibitory effect on the complex 1 of the mitochondrial respiratory chain, which is 
thought to contribute to its anti-hyperglycaemic effect. Metformin is also thought 
to have a protective effect on cardiovascular disease (CVD), the most common 
complication in T2D. It is widely accepted that T2D is an inflammatory state thus 
it is not surprising that T2D patients have 2-4 times higher risk in developing 
CVD. Furthermore, the pathology of T2D has been proposed to involve 
dysfunctioning mitochondria, the organelle of energy sensing and production. The 
use of metformin, a mitochondria inhibitor, in cells under mitochondrial stress led 
us to speculate the physiological responses that ensue. 
To understand metformin‟s mode of action and its involvement in inflammation 
processes the human monocytic leukemia THP-1 cells were used in this study. 
Since studies of metformin on this cell type is scarce if not non-existence the first 
task was to determine its cytoxicity in this cell line. Next the mRNA and protein 
expressions of heat shock protein 60 (Hsp60), a mitochondrial stress marker, was 
determined in metformin-treated THP-1 cells. Further, various cell types have 
shown surface expressed Hsp60 under stress conditions. Thus the study here 
attempted to optimise the detection of surface Hsp60 in THP-1 cells, as human 
Hsp60 has been shown to induce innate immune response. Localisation of Hsp60 
on the cell surface in metformin-treated cells may exacerbate the 
already-inflammed state of T2D. Lastly, metformin‟s effect on PMA-stimulated 
monocyte differentiation was determined by the mRNA expression of CD14, a 
surface receptor on macrophages.  
ii 
The results here agreed with published data that metformin at therapeutic 
concentrations are not cytotoxic and is a mild inhibitor of mitochondrial 
respiration. We also provide evidence that metformin up-regulated the 
mitochondria stress protein, Hsp60, in a time- and dose-dependent manner. In 
addition, live cell Hsp60 immunocytochemistry proved to be a promising method 
for surface Hsp60 detection in THP-1 cells. Finally, at the therapeutic 
concentration metformin caused a significant up-regulation in cd14 expression, 
which contradicts with much acclaimed protective effect of metformin in the 
literature. 
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1 
1 Literature Review and Research Aims 
This chapter reviews the current literature on the pharmacology of an anti-diabetic 
agent, metformin. A review on the role of heat shock protein 60 (Hsp60) is also 
provided and focuses particularly in the context of type 2 diabetes and 
cardiovascular disease. Finally, the proposed hypothesis will be explained and 
presented at the end of the chapter. 
 
1.1 Type 2 Diabetes Mellitus 
1.1.1 Statistics 
Type 2 Diabetes (T2D) is the most common metabolic disease in the world. Not 
only it reduces the quality of life for patients and their family, the cost of health 
care exceeds $130 billion dollars per year in the United States alone (Petersen 
2003). Since December 2000, diabetes has been identified as a priority health 
objective and „improving diabetes services‟ has been listed as one of 10 targets for 
the New Zealand health sector (Ministry of Health 2007). Here, 5,000 adults were 
newly diagnosed and approximately 81,000 people were known to have diabetes 
in the year 1996 (Ministry of Health 2002). Furthermore, people with Māori and 
Pacific origins have three times higher incident rates than Europeans, and are 
more than five times more likely to die from diabetes (Ministry of Health 2002). 
In addition, not only do patients with T2D have an increased risk of 
cardiovascular disease (CVD), but it is also the leading cause of death among 
these patients, accounting for 40% - 56% of all deaths, as documented by several 
studies (de Marco et al. 1999; Roper et al. 2002). The common association of 
T2D with CVD will be reviewed in Chapter  1.1.4. 
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1.1.2 Definitions of Diabetes 
The World Health Organization (WHO) (World Health Organization 2006) 
recommended definition of diabetes and intermediate hyperglycaemia states are 
summarized in Table  1.1. Impaired fasting glucose (IFG) and impaired glucose 
tolerance (IGT) are stages in the development of diabetes and is listed in the order 
of severity of disease. There have been recommendations that glycated 
haemoglobin (HbA1c) should be included in diagnosis and risk categories for 
diabetes and the WHO is currently undergoing review. 
Table  1.1 – Definitions of type 2 diabetes 
Condition 
Fasting plasma glucose 
mmol/l (mg/dl) 
2-h plasma glucose* 
mmole/l (mg/dl) 
Normal < 6.1 (110) < 7.8 (140) 
Impaired fasting glucose (IFG) 6.1 to 6.9 (110 to 125) < 7.8 (140) 
Impaired glucose tolerance (IGT) < 7.0 (126) ≥ 7.8 (140) and <11.1 (200) 
Diabetes ≥ 7.0 (126) ≥ 11.1 (200) 
*Venous plasma glucose 2 hours after 75 g of glucose ingested. 
 
1.1.3 Pathogenesis of T2D 
It is now clear that disease progression of T2D involves insulin resistance (IR) in 
the early stages and eventually defects in insulin secretion by pancreatic β cells 
lead to the onset of hyperglycemia. There is accumulation evidence suggesting 
that these features of T2D are attributable to defects in mitochondria, the 
organelles that govern energy production in the cell (Lowell & Shulmanz 2005; 
Mulder & Ling 2009).  
In order to utilize blood glucose, β cells of the pancreatic islets of Langerhans 
must act as sensors to vary insulin output to the prevailing blood glucose level. 
Insulin is crucial for promoting glucose storage and the prevention of glycogen 
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breakdown. Glucose sensing by β cells is therefore essential for maintaining 
glucose homeostasis. The chain of events followed by glucose sensing include: 
oxidative mitochondrial metabolism leading to an increased ATP:ADP ratio, 
inhibition of an ATP:ADP-regulated potassium channel, plasma membrane 
depolarisation, calcium influx, and, finally insulin secretion. Insulin resistance is a 
condition where skeletal muscle and liver, the two key insulin-responsive organs, 
require higher levels of insulin for glucose sensing. Unable to uptake glucose by 
peripheral tissues, failure to synthesize glycogen and suppress glucose production 
in the liver all contribute to hyperglycaemia. 
Several lines of evidence support T2D pathogenesis by mitochondrial dysfunction. 
First, accumulating intracellular fatty acids (fatty acyl CoAs, diacylglycerol) have 
been shown to cause IR by the suppression of insulin signaling, which can be 
attributable to defects in mitochondrial fatty acid oxidation. Second, IR 
individuals were found to have a lower ratio of type 1 to type 2 muscle fibers, 
where the former contain more mitochondria than the latter. It was thought that 
peroxisome proliferator-activated receptory coactivator 1α, one of the genes that 
regulate mitochondrial biogenesis, is down-regulated in these individuals. Third, it 
was found that in T2D β cell mass is reduced relatively to matched individuals 
(with similar degrees of IR). The cause of this is unknown, but a mitochondrial 
regulated apoptosis mechanism has been suggested. In addition, an inner 
mitochondrial membrane protein called uncoupling protein-2 (UCP-2) has been 
shown to negatively regulate glucose-stimulated insulin secretion. UCP-2 is an 
integral membrane protein that can leak protons across the membrane when 
activated, leading to decreased ATP production. The expression of UCP-2 was 
shown to be stimulated by hyperglycaemia and hyperlipidaemia both in vivo and 
in vitro, suggesting a pathogenic role. It was also found that superoxide, a 
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byproduct of the electron transport chain, stimulates the activity of UCP-2 when 
added exogenously to isolated mitochondria, ultimately resulting in β cell 
dysfunction. All of the above defects might be secondary to chronic increased 
exposure to both glucose and fatty acids, a situation usually associated with 
obesity. 
 
1.1.4 Diabetes and Complications 
Diabetes is a „metabolic syndrome‟ where it is associated with pathophysiological 
conditions such as hyperglycaemia, hyperinsulinaemia, dyslipidaemia, abdominal 
obesity, raised blood pressure, pro-inflammatory state and atherosclerosis (Bailey 
2008). Individuals with T2D have a two- to fourfold increase in CVD incidence 
than non-diabetic individuals (Zarich 2009). Chronic hyperglycaemia and insulin 
resistance both have important roles in the pathogenesis of CVD. Cardiovascular 
disease is a collective term for microvascular and macrovascular diseases. The 
former refers to blindness, end-stage renal disease and a variety of debilitating 
neuropathies whereas the latter refers to atherosclerotic events such as myocardial 
infarction (MI, heart attack), stroke and limb amputation (Brownlee 2001). 
Monocyte recruitment and subsequent differentiation into macrophage is an 
important step in early atherosclerosis development (Libby 2002; Ludewig & 
Laman 2004). Figure 1.1 depicts an atherosclerotic event where circulating 
monocytes attach to the subendothelial space by interacting with adhesions 
molecules such as vascular cell adhesion molecule-1 (VCAM-1). The following 
migration into the intima is driven by a gradient of chemoattractants. A dominant 
chemokine, monocyte chemoattractant protein-1 (MCP-1), participates in this 
process by interacting with its receptor CCR2. The monocytes being retained in 
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the intima eventually become macrophages, expressing scavenger receptors such 
as CD36 that bind modified forms of low density lipoprotein (LDL) (oxidized or 
glycated). Such macrophages are termed foam cells, named after their foamy 
appearance under the microscope. Foam cells then amplify inflammation at the 
lesion through the production of cytokines, reactive oxygen species (ROS), and 
tissue-damaging compounds such as matrix metalloproteinases (MMP). The 
accumulation of foam cell along with T helper cells results in the progression of 
the atherosclerotic lesion which can ultimately lead to a thrombotic event and the 
rupture of an endstage plaque (Ludewig & Laman 2004).  
 
 
 
 
 
 
 
 
Figure  1.1 – Recruitment of monocyte to nascent atherosclerotic plaque. (Adapted from 
Libby (2002))  
6 
A closer look at monocytes reveals that CD14 is a specific marker for human 
monocytes (Passlick et al. 1989). CD14 functions as a receptor on the cell 
membrane for lipopolysaccharide (LPS)-binding protein/LPS complex recognition. 
In a study by Fogelstrand (2004), elevated circulating CD14+ monocyte, 
C-reactive protein (CRP), interleukin (IL)-6, and adhesion molecules intercellular 
endothelial cell (ICAM-1) and VCAM-1 were measured in diabetic women aged 
64. The IGT group had values between the diabetic and normal group. Another 
study by Cipolletta (2005) further showed that poorly controlled diabetic 
monocytes are functionally activated as indicated by CD36 and CD68 expression. 
These two scavenger receptors are associated with the maturation of monocytes 
toward macrophages (Tsukamoto et al. 2002). In agreement with the 
atherosclerotic model above, increase in CD36 surface expression was paralleled 
by an increase in oxLDL uptake (Cipolletta et al. 2005). Furthermore, monocytes 
from a poor glucose control group had significantly increased ability to attach to 
endothelial cells.  
 
In summary, T2D is a metabolic syndrome and mitochondrial dysfunction is 
thought to play a role in disease onset. Meanwhile, metabolic imbalance is 
commonly associated with imbalanced immune responses (Wellen & Hotamisligil 
2005), in the case of T2D, a chronic low-grade inflammation is associated with 
the disease. Elevated cytokines and activated monocytes present in diabetic 
circulation are also seen in circulation of vascular inflammation. Not surprisingly, 
CVD is the most common complication in T2D and diabetes is considered a 
“CVD risk equivalent” (Zarich 2009). 
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1.2 Metformin 
There are nine classes of approved drugs to treat T2D: insulin, sulphonylureas 
(SU), glinides, biguanides, α-glucosidase inhibitors, thiazolidinediones, 
glucagon-like peptide 1 mimics, amylin mimetic and dipeptidyl peptidase 4 
inhibitors, either as monotherapy or in combination. The current recommendation 
by two major international diabetes associations is to initiate metformin therapy at 
diagnosis concurrently with lifestyle intervention (Nathan et al. 2009). 
 
1.2.1 Chemistry and History  
The biguanide family of anti-hyperglycaemic agents includes phenformin and 
metformin (Figure  1.2). They are the active glucose-lowering compound of French 
lilac (Gallega officinalis), of which the use can be traced back to the medieval 
times (Witters 2001). Although successful in the treatment of T2D, phenformin 
was withdrawn in the 1970s due to its association with lactic acidosis (Williams & 
Palmer 1975), leaving metformin as the only biguanide available today.  
 
 
 
 
 
 
Figure  1.2 – Chemical structures of phenformin and metformin. (Adapted from Goodarzi 
& Bryer-Ash, 2005). 
 
 
8 
Metformin, chemical name N-1,1-dimethylbiguanide, is a white crystalline 
powder and is freely soluble in water. It is a weak base exhibiting a cationic 
charge at physiological pH (Wiernsperger 1999). Without the phenyl-ethyl ring 
that the phenformin possess, metformin is more polar and hence less lipid soluble.  
Commercial name of metformin as monotherapy include Fortamet®, 
Glucophage®, Glucophage® XR, Glumetza®, and Riomet® (MedlinePlus 2008). 
Contra-indications include renal and hepatic disease; cardiac or respiratory 
insufficiency; any hypoxic condition; severe infection; alcohol abuse; history of 
lactic acidosis; pregnancy and lactation (Bailey 2008). 
In humans, metformin disposition is apparently unaffected by the presence of 
diabetes and the therapeutic levels range from 0.5 – 2.0 mg/L (around 3 – 15 μM) 
(Scheen 1996). Similarly, in normal and diabetic mice, the fasting plasma level of 
metformin is close to 10 μM and it hardly exceeds 100 μM after oral tablet intake 
(Wilcock & Bailey 1994). In the intestine the concentration can reach 10 mM and 
in the liver it is slightly higher than plasma levels. However, the concentrations in 
peripheral tissues such as skeletal muscle or fat are not much different from 
plasma levels (Wilcock & Bailey 1994; Wiernsperger 1999). It is therefore 
important to work within clinically relevant ranges of metformin concentration in 
this project. 
 
1.2.2 Cytotoxicity of Metformin 
The cytotoxicity effect of metformin has been analysed in detail by Dykens et al 
(2008). The IC50 values of phenformin and metformin on primary human 
hepatocyte, and HepG2 cells grown in either galactose or glucose are shown in 
Table  1.2. HepG2 cells grown solely on galactose were shown to be more reliant 
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on oxidative phosphorylation, thereby rendering the cells more susceptible to 
mitochondrial impairment (Marroquin et al. 2007; Dykens et al. 2008).  
Table  1.2 – IC50 values (μM) of metformin and phenformin in three cell models. 
Biguanide 
Primary human 
hepatocytes 
HepG2 in 
galactose 
HepG2 in glucose 
Metformin 657 1430 >2000 
Phenformin 11.7 12.9 >500 
 
The group then found that in primary human hepatocytes exposed to metformin 
concentration at 1 mM for 24h began to show dissipated membrane potential (∆Ψ) 
and induced ROS and at 2 mM there was a depletion of reduced glutathione (GSH, 
another measure of oxidative stress). At concentrations below 500 μM there was 
no detectable effect on these indices. However, 12.5 μM phenformin caused all of 
the above deleterious effects. It was also noted that cell numbers did not decrease 
at 24 h, indicating these concentrations were not immediately lethal. 
Together these data confirm phenformin is much more potent than metformin and 
that metformin range below 500 μM had no detectable deleterious effects on these 
hepatic cell types. 
 
1.2.3 Metformin as an Anti-Hyperglycemic Agent 
It is well documented that metformin‟s major action is to reduce hepatic glucose 
production, which is increased at least twofold in T2D patients (reviewed by 
(Kirpichnikov et al. 2002). Metformin treatment was shown to decrease fasting 
plasma glucose by 25 – 30% in various studies and this was attributable to a 
reduction in the rate of gluconeogenesis (Kirpichnikov et al. 2002).  
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The second most important effect of metformin is the increase in 
insulin-stimulated glucose uptake in peripheral tissues (mainly skeletal muscle) 
(Kirpichnikov et al. 2002). Enhanced muscle uptake of insulin, increased insulin 
receptor tyrosine kinase activity, increased glucose transporter-4 (GLUT4) 
translocation and transport have been reported as a response to metformin therapy 
(reviewed by Goodarzi & Bryer-Ash 2005). 
Other beneficial effects include reduction of triglycerides, total cholesterol, LDL 
cholesterol levels, and an increase in HDL cholesterol. Futhermore, in contrast 
with many other anti-hyperglycaemic medications, metformin is known to 
maintain or reduce the weight of patients. However, it may induce adverse 
gastrointestinal effects, interfere with vitamin B12 absorption and in rare cases, 
induce lactic acidosis. See Table  1.3 for summarized effects of metformin.  
Recently, there are data from trials and in vitro experiments suggesting that 
metformin has a vascular protective effect. This aspect will be discussed in detail 
in Chapter  1.2.6. 
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Table  1.3 – Favourable and adverse effects of metformin. (Adapted from Goodzari & 
Bryer-Ash 2005) 
 Favourable effects Adverse effects 
Generally accepted Improved glycaemic control 
(fasting plasma glucose by 3-4 
mmol/l and HbA1c by 1.5-2%) 
Reduced triglycerides 
Reduced total cholesterol 
Reduced LDL-cholesterol 
Weight stability/reduction 
Stabilise/reduce serum insulin 
level 
Gastrointestinal (diarrhea, 
abdominal discomfort) 
Lactic acidosis 
Metallic taste 
Reduced serum B12 levels 
Some evidence Blood pressure reduction 
Increased HDL-cholesterol 
Increased fibrinolytic activity 
(PAI-1 levels reduced) 
Reduced platelet aggregation 
Reduced fibrinogen levels 
Improved vascular relaxation 
Reduced CRP 
 
 
1.2.4 Molecular Mechanism of Metformin 
Despite decades of clinical use, the exact mechanism of metformin action is yet to 
be definitively determined. A variety of possible mechanisms has been 
demonstrated to explain its hepatic effect, including phosphorylation of insulin 
receptor and insulin receptor substrate-2, inhibiting key enzymes in the 
gluconeogenic pathway, activation of pyruvate kinase, inhibition of hepatic 
glucagon effects and reduction in hepatic uptake of glucogenic substrates (lactate, 
alanine) (reviewed by Goodarzi & Bryer-Ash 2005). Alternatively, Wiernsperger 
(1999) proposed that metformin exerts its effects through physically normalising 
the membrane fluidity in the diabetic state, therefore restoring protein-protein or 
12 
protein-lipid interactions required for proper functioning of the processes 
regulating glucose transport/metabolism. However, two mechanisms dominate the 
literature, which propose that metformin functions through (1) inhibition of the 
mitochondrial respiratory chain and (2) activation of the AMPK pathway. 
 
1.2.4.1 Metformin inhibits complex 1 
Accumulating data support that the metformin‟s primary site of action to be the 
complex I of the mitochondrial respiratory chain (Owen et al. 2000; Brunmair et 
al. 2004; Guigas et al. 2004).  
Owen et al. (2000) demonstrated that there is a time- and dose-dependent 
inhibition of respiration in metformin-treated rat hepatoma cells. Metformin (50 
µM) caused 12.6 ± 4.3 and 29.4 ± 7.7 % inhibition after 24 and 60 h, respectively; 
whereas 100 µM metformin caused 25.8 ± 3.4 and 37.1 ± 10.0 % inhibition, 
respectively, when glutamate+malate was used as substrate. There was no 
inhibition on succinate oxidation, indicating that metformin does not affect 
complex 3 of the respiratory chain. The group then used isolated mitochondria to 
show that inhibition of respiration increased with increasing metformin 
concentrations. Concurrent results were also seen in submitochondrial particles 
(SMPs), confirming that metformin targets at the complex 1 of the respiratory 
chain and not at the dehydrogenases producing NADH. Liver mitochondria 
isolated from rats treated with 50 mg metformin daily for 5 days showed 
approximately 10% in glutamate+malate oxidation compared with control. The 
authors explained that little inhibition in vivo was due to a lost in accumulated 
metformin during mitochondria isolation however changes in liver metabolite 
concentrations are characteristic of complex 1 inhibition. 
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Similarly, inhibition of complex 1 by metformin was seen in intact KB cells, an 
oral squamous carcinoma cell line (Guigas et al. 2004). After 30 min incubation 
of 10 mM metformin with permeabilised KB cells, oxygen consumption was 
reduced by 33% (p < 0.01) when glutamate and malate was used as substrate. This 
reduction in oxygen consumption was comparable to that when CCCP (inhibitor 
of oxidative phosphorylation that abolishes the mitochondrial membrane proton 
gradient) was added, but not in seen when succinate and malate was used as 
substrates. To further confirm this, NADH decylubiquinone reductase activity was 
measured in permeabilised KB cells pre-incubated with or without 10 mM or 100 
μM metformin. Complex 1 activity was measured after hypo-osmotic 
shock-induced mitochondrial membrane rupture, and NADH oxidation monitored 
before and after the addition of 6 μM rotenone. Rotenone-sensitive activity of 
complex 1 was reduced by 34% (P < 0.01) and 24% (P < 0.05) in 10 mM and 100 
μM metformin, respectively. As a control, citrate synthase activity was not altered. 
Interestingly, thiazolidinediones (TZDs), another class of anti-diabetic drug that 
predominantly increases insulin-stimulated glucose uptake in skeletal muscle, was 
also shown to inhibit complex 1 of the respiratory chain (Brunmair et al. 2004). 
The effects of TZDs and metformin to some extent resemble those of exercise and 
AICAR (5-aminoimidazole-4-carboxamide- 1-β-D-ribofuranoside). TZDs and 
metformin both reduce the ratios of ATP to AMP, ATP to ADP, and 
phosphocreatine to creatine in vitro (reviewed by Brunmair et al. 2004). AICAR, a 
mimic of AMP, is known to activate the enzyme AMP-activated protein kinase, 
which promotes catabolic pathways while suppress anabolic ones and causes 
insulin sensitisation in the long term (Hardie et al. 2006). This finding supports 
the hypothesis that changes in the cellular energy status could have a role in the 
pharmacological and physiological modulation of insulin activity (Brunmair et al. 
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2004).  
 
1.2.4.2 Metformin activates the AMP-activated protein kinase 
The AMP-activated protein kinase (AMPK) is a phylogenetically conserved 
heterotrimer protein that functions as a metabolic sensor. It is activated by stimuli 
that either inhibit ATP production (e.g. hypoxia, hyperglycaemia) or that 
accelerate ATP consumption (e.g. exercise) which lead to an increase in AMP:ATP 
ratio. AMPK activation requires the phosphorylation of Thr172 on the α subunit in 
a highly sensitive manner. The downstream targets of AMPK include several 
biosynthetic enzymes such as acetyl-CoA carboxylase (ACC), 
hydroxymethylglutaryl-CoA reductase, glucagon synthase, and endothelial nitric 
oxide synthase (eNOS) (Hardie et al. 2006).  
Several studies have shown that AMPK is a target of metformin. Zou et al (2004) 
demonstrated a dose-dependent AMPK activation in bovine aortic endothelial 
cells (BAEC) by metformin (100-500 μM), and this activation is mediated by 
mitochondrial generated reactive nitrogen species (RNS). The authors deduced 
that the product of complex 1 inhibition, O2
̇ -
, reacts with NO to form ONOO
-
, 
which is required in AMPK activation. This was derived from (1) BAECs 
depleted of functional mitochondria (ρ˚-BAECs) did not activate AMPK by 
metformin, and (2) over-expression of superoxide dismutase (SOD) or inhibition 
of NOS blocked metformin-induced AMPK activation. Zou et al (2004) also 
showed activation of PI3K by metformin or ONOO
-
 increased association of 
LKB1 with AMPK, thereby enhancing AMPK activity. LKB1 is one of the 
upstream kinases that can phosphorylate Thr172 and its expression appears to be 
constitutive (Hardie et al. 2006) and this is consistent in this experiment. 
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The same group furthered discovered that AMPK activation by metformin led to 
the phosphorylation of eNOS in BAECs and its association with heat shock 
protein 90 (Hsp90), resulting in increased activation of eNOS and NO bioactivity 
(Davis et al. 2006). The association of Hsp90 with eNOS is considered an 
important step in controlling eNOS activity (Davis et al. 2006) and NO is known 
to improve vasorelaxation. In high glucose-induced cells, metformin relieved 
inhibited AMPK and eNOS activity and further decreased the expression of 
adhesion molecules and endothelial apoptosis.  
Hattori and collegues (2006) demonstrated that metformin dose-dependently 
inhibited tumor necrosis factor α- (TNFα)-induced nuclear factor-κB (NF-κB) 
activation and TNFα-induced IκB kinase activity in human umbilical vein 
endothelial cells (HUVECs). The outcome is attenuated expression of various 
pro-inflammatory cytokines and cell adhesion molecules, such as VCAM-1, 
E-selectin, intercellular adhesion molecule-1 (ICAM-1), and monocyte 
chemoattractant protein-1 (MCP-1). 
The data from Davis et al (2006) and Hattori et al. (2006) suggest that metformin 
improves endothelial functions and may reduce cardiovascular events in patients 
with T2D. Activation of AMPK is the common pathway in these two studies and, 
not surprisingly it has been reviewed whether new therapeutic agents should target 
AMPK to control metabolic disease and vascular disease (Wong et al. 2009).  
 
A centrally important question is: which is the primary target of metformin? There 
has been no report of metformin binding to complex 1 or AMPK, although there is 
evidence that the biguanide family is a substrate of the organic cation transporter 
(OCT)-1 (Wang et al. 2003; Sogame et al. 2009). Regardless of the uptake 
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mechanism, the site of action that results in metformin‟s anti-hyperglycaemic 
effects seems to be complex 1 of the mitochondrial respiratory chain. Activation 
of AMPK could be the secondary effect due to an increase in AMP:ATP ratio 
caused by inhibited oxidative phosphorylation. If AMPK represents the primary 
target, it is possible that one of the proteins in the cascade of phosphorylation 
events can locate on the outer mitochondrial membrane, thereby indirectly affect 
complex 1 (Guigas et al. 2004).  
 
1.2.5 Metformin, Oxidative Stress & More 
It is generally recognized that hyperglycaemia contributes to vascular 
complications by mitochondria-generated oxidative stress (Nishikawa et al. 2000) 
(Brownlee 2001). Complex 1 and 3 are two main sites of superoxide generation in 
the inner mitochondrial membrane (Kwong & Sohal 1998).   
Indeed, metformin, being an inhibitor of the complex 1, has been shown to reduce 
ROS production in rat liver mitochondria via the reverse electron flux through the 
complex 1 while forward flux-related ROS production was unaltered (Batandier et 
al. 2006).  
In intact KB cells metformin completely prevented cell death induced by an 
exogenous glutathione-oxidizing agent, t-butyl hydroperoxide (t-BH), 
independent of the concentration used (100 µM or 10 mM). This was confirmed 
by determining the release of cytochrome c from the mitochondrial 
intermembrane space to the cytoplasm, a pro-apoptotic event in the commitment 
to cell death (Guigas et al. 2004). The mechanism by which metformin prevented 
cell death involved the modulation of mitochondrial permeability transition pore 
(PTP) opening, which was exclusive to complex 1 inhibitors (Guigas et al. 2004). 
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Similarly, metformin prevented high glucose-induced cell death in a human 
dermal microvascular endothelial cell line, HMEC-1 (Detaille et al. 2005). It was 
deduced that metformin also prevented PTP opening in HMEC-1 cells under 
glucose-induced oxidative stress. The calcium retention capacity is related to 
potency of inhibition on complex 1 as shown by studies using rotenone. 
In contrast, a study by Carvalho and colleagues (2008) reported that metformin 
treatment resulted in a slight, although not significant, increase in H2O2 
production in rat liver mitochondria. A short term trial involving fifteen T2D 
patients treated with metformin also showed an elevation in oxidative stress as 
measured by malidialdehyde levels (Skrha et al. 2007). This is also consistent 
with the fact that induction of ONOO
-
 was required for the activation of AMPK as 
mentioned above (Zou et al. 2004).  
Further, metformin exacerbated Ca
2+
-induced mitochondrial PTP opening in a 
concentration-dependent manner. Similarly, metformin in cultured glioma cells 
caused mitochondrial depolarization- and oxidative stress-dependent apoptosis 
(Isakovic et al. 2007).  
The conflicting result reflects the central role that mitochondria play in cell 
viability, as well as the complexity of the many metabolic and oxidative equilibria 
and pathways that converge at the level of mitochondrial integrity (Dykens et al. 
2008). 
 
1.2.6 Metformin & Vascular Disease 
Adding to the effect of metformin on lowering blood glucose, several trials 
indicate that metformin has protective effects on CVD compared with other 
treatments. Metformin has also shown to reduced development of atherosclerotic 
18 
lesions in animal models. Other modest favourable effects include reduced 
dyslipidaemia, reduced pro-inflammatory cytokines and adhesion molecules, 
improved glycation status, and anti-thrombotic effects. It should be noted that 
these beneficial effects could be secondary effects due to reduced weight/blood 
glucose/insulin rather than attributed to direct properties of metformin. 
 
1.2.6.1 Evidence from trials 
A summary of vascular outcome by metformin treatment in various trials is listed 
in Table  1.4.  
In a sub-study of the United Kingdom Prospective Diabetes Study (UKPDS) it 
was found that early and intensive glycaemic control with metformin reduced the 
risk of MI and diabetes-related death by 39% and 42%, respectively, compared 
with the conventional (diet) treated group in overweight T2D patients. Since 
SU/insulin had similar glucose-lowering efficacy as metformin but did not reduce 
myocardial infarction significantly, the vasoprotective by metformin was thought 
to be independent of the level of HbA1c (Turner et al. 1998). Although UKPDS 
did not provide evidence on CVD risks in non-obese T2D patients, recent short 
trials have demonstrated metformin reduced biomarkers for CVD risk compared 
with repaglinide, an insulin secretagogue (Lund et al. 2008).  
In contrast to the above, the „A Diabetes Outcome Progression Trial‟ (ADOPT), 
which followed 4360 newly diagnosed T2D patients allocated to rosiglitazone 
(glitazone), glyburide (SU), or metformin, revealed that there were fewer CVD 
events in the glyburide group than the others (Kahn et al. 2006).  
Further, in the DIGAMI-2 trial, T2D patients followed after a myocardial 
infarction showed there were no differences in CVD mortality between the 
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intervention groups with insulin, SU or metformin. While insulin therapy 
increased the risk of a new MI, metformin had a protective effect (Mellbin et al. 
2008). 
A relative small „Hyperinsulinemia: the Outcome of its Metabolic Effects‟ 
(HOME) trial allocated 390 patients to either placebo or metformin as an add-on 
to ongoing insulin therapy. There was no significant decrease for the risk of 
primary outcome, which is an aggregate of microvascular disease, CVD and 
mortality. In addition, although secondary microvascular disease outcome was not 
significant, metformin significantly reduced the risk of secondary CVD outcomes 
such as myocardial infarction, stroke, and peripheral arterial reconstruction by 
39%. The hypoglycaemic efficacies were comparable in both groups however 
changes in body weight in the metformin/insulin group partly explained the 
difference in CVD (Wulffele et al. 2002). 
In a three months trial, metformin reduced carotid intima-media thickness as 
measured by ultrasound (Bailey 2008). In several animal trials, metformin was 
shown to reduce plaque formation. In one experiment, metformin reduced aortic 
plaque formation even without significantly affecting blood lipids in rabbits fed a 
high cholesterol diet (Bailey 2008). 
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Table  1.4 – CVD outcome by anti-hyperglycaemic agents in trials.  
Trial 
Sample 
size 
Specifications Treatment groups 
Follow up 
period 
Major findings relating to vascular outcome 
UKPDS (United 
Kingdom Prospective 
Diabetes Study) 
753 Overweight 
T2D patients 
Conventional (diet) 
or intensive 
glycaemic control 
with MET or 
SU/insulin 
Average of 
10 years 
 MET significantly reduced risk of MI (39%), diabetes-related death (42%), and 
all-cause mortality (36%). 
 MET significantly reduced the incidence of CVD compared with SU/insulin. 
 MET did not reduce the number of patients with microvascular outcome 
measures. 
 The study did not separate non-obese patients thus there is lack of data for CVD 
risk in these patients. 
ADOPT (A Diabetes 
Outcome Progression 
Trial) 
4360 Newly 
diagnosed T2D 
patients 
Rosiglitazone, 
glyburide, or MET 
4 years  Not statistically powerful enough to detect differences in CVD risk, only that 
there were fewer CVD events in the glyburide group than the other two. 
DIGAMI-2 1181 T2D patients 
after MI 
Insulin, SU, or 
MET 
2 years  MET had a protective effect on the development of a new MI. 
HOME 
(Hyperinsulineamia: 
the Outcome of its 
Metabolic Effects) 
390 T2D Placebo or MET in 
addition to ongoing 
insulin 
4.3 years  No significant decrease for risk of primary outcome – aggregate microvascular 
disease 
 MET significantly reduced the risk of secondary CVD outcome by 39% but not 
significant in microvascular outcome. 
 Changes in body weight partly explained the difference in CVD risks. 
Abbreviations: CVD, cardiovascular disease; MET, metformin; MI, myocardial infarction; SU, sulphonylureas; T2D, type 2 diabetes. 
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1.2.6.2 Potential mechanism 
Cell culture and animal studies have shown a possible association between insulin 
resistance, compensatory hyperinsulinaemia and the development of 
atherosclerosis (reviewed by Hemmingson et al. 2009). Hyperglycaemia, on the 
other hand, is also a risk factor for CVD. It is possible the anti-atherogenic effects 
exerted by anti-hyperglycaemic agents are attributable to their improvement on 
insulin sensitivity, thereby reduce CVD risks. Similarly, lowering blood glucose 
could account for the beneficial effects on CVD development. Metformin seems 
to have additional protective effect independent of these mechanisms by 
improving several aspects of cardio-metabolic dysfunction that commonly occur 
in T2D based on various in vitro experiments. The following is an overview of the 
effects of metformin on the main recognized pathophysiological parameters 
associated with CVD (modified from Bailey 2008): 
(1) Blood pressure – There is no measurable changes in blood pressure by 
metformin.  
(2) Lipids – In diabetes, increased free fatty acids contributes to secretion of 
vLDL, which when modified have high affinity for scavenger receptors on 
macrophages. Lipid laden macrophages, namely foam cells, participate in 
early plaque formation. Metformin improves dyslipidaemia in diabetic 
patients, decreases oxidative stress and reduces lipid oxidation by lowering 
blood glucose. 
(3) Endothelial function – Metformin was shown to increase 
endothelium-dependent vasodilation in a three month trial (Mather et al. 2001) 
possibly by inducing eNOS activation and improving NO bioactivity (Davis et 
al. 2006). Metformin was also shown to reduce monocyte adhesion to human 
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ECs by decreased expression of VCAM-1, ICAM-1 and E-selectin in 
endothelial cells (ECs). The effect of lowered advanced glycation endproducts 
(AGEs) could also contribute to the reduced expression of adhesion molecules. 
Metformin also reduced differentiation of cultured human monocytes into 
macrophages and foam cells (Mamputu et al. 2002).  
(4) Inflammation – Metformin has been shown to reduce CRP concentrations in 
T2D independently of glycaemic control. Metformin also reduced 
TNFα-induced of NF-κB activation in HUVECs (Hattori et al. 2006). 
(5) Glycation and oxidative stress – Hyperglycaemia-induced AGEs can activate 
AGE receptors on ECs and macrophages, leading to production of cytokines 
and ROS. Metformin was shown to reduce the formation of AGEs 
(Beisswenger et al. 1999). Several studies have shown metformin reduced 
production of ROS in cell cultures (Ouslimani et al. 2005) and partially 
reverse the reduced antioxidant defenses in T2D (Libby 2002) 
(6) Anti-thrombotic effects – Metformin has been shown to reduce 
hypercoagulation and increase fibrinolysis by decreasing the levels of 
plasminogen activator inhibitor (PAI)-1 and increasing tissue plasminogen 
activator activity (Grant 1996). Furthermore, metformin decreased platelet 
aggregation in T2D patients. These anti-thrombotic actions seem to be 
independent of the anti-hyperglycaemic effect (Grant 2003). 
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Overall, these effects might contribute to the beneficial effects of metformin on 
the risk of CVD in T2D. However, what still remain unclear is (1) whether there is 
a direct causal relationship between lowering blood glucose and the risk of 
developing CVD, and (2) it has still not been clarified which anti-diabetic 
interventions prevent CVD to the greatest extent in patients with T2D, despite 
much research. Metformin (and glitazones) may have a beneficial effect on CVD 
risk but conclusive documentation is yet unavailable. 
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1.3 Heat Shock Proteins 
Heat shock proteins (HSPs) are a group of highly phylogenetically conserved 
proteins present in all prokaryotes and eukaryotes. First discovered in temperature 
shocked Drosophila in 1962, then it was recognised that heavy metals, metabolic 
poisons, hypoxia, and free radicals also led to the production of these stress 
proteins (Shamaei-Tousi et al. 2007a). In actual fact, HSPs are constitutively 
expressed and they serve as molecular chaperones where they bind to nascent 
polypeptide chains and partially folded proteins to prevent their aggregation and 
misfolding. HSPs are also involved in the degradation of aged or damaged 
proteins. Under cellular stress, however, the expression of these stress proteins can 
be induced to prevent cellular damage.  
HSPs can be classified into six families, the small HSPs (sHSP), HSP40, 60, 70 
90, and HSP110, based on their molecular mass. A summary of mammalian HSP 
families is listed in Table  1.5. 
Recently HSPs have been detected on the cell surface and the extracellular milieu 
(see Chapter  1.3.3) and their immunoregulatory role has been established. 
Members in the HSP60 and HSP70 families have been widely studied for their 
ability to stimulate innate and adaptive immunity as well as their abundance in 
cancer cells. The occurrence of these proteins is particularly important in diseases 
such as diabetes and CVD as (1) diabetes is associated with a low level chronic 
inflammation, (2) cells in the diabetic state are in stress due to hyperglycaemia, 
and (3) (endothelial) inflammation is involved in the pathogenesis CVD, a major 
complication in T2D. In later chapters the association of Hsp60 with T2D and 
CVD will be reviewed. 
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Table  1.5 – Major mammalian HSP families. (Adapted from Habich and Burkart 2007) 
Families Size (KDa) Prominent members Localisation 
Small HSPs 12 – 43 B-crystallin 
Hsp27 
Cytoplasm 
Cytoplasm, nucleus 
HSP40 ~40 Hsp40 Cytoplasm, nucleus 
Hsp60 ~60 Hsp60 
TCP1 
Mitochondria 
Cytoplasm 
HSP70 ~70 Hsp70 
Hsc70 
Grp78/BiP 
Cytoplasm 
Nucleus 
Cytoplasm, ER 
HSP90 ~90 Hsp90 (α and β) 
Gp96 
Cytoplasm 
ER 
HSP110 ~110 Hsp110 Cytoplasm 
 
1.3.1 Heat Shock Proteins in the HSP60 Family 
Proteins in the HSP60 family have a size of around 60 KDa and they have a high 
sequence homology between species. Hsp60 of bacterial origin have homology 
higher than 97% at their protein levels, while prokaryotic and human Hsp60 show 
over 70% homology at most conserved regions. 
The E. coli GroEL is a well-studied member of the HSP60, known for its role in 
assisting protein folding alongside its cofactor GroES (Hsp10) in an 
ATP-dependent manner. Crystal structure of GroEL showed that it exists as two 
identical heptameric rings stacked back to back to form a central cavity (Figure 1.3) 
(Chen & Sigler 1999). In the presence of adenine nucleotides the GroES binds to 
the apical domain of the GroEL complex acting like a cap. The apical domain also 
serves as binding site for unfolded protein substrate (Levy-Rimler et al. 2002). 
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Figure  1.3 – van der Waals space filling models of the GroEL-GroES-(ADP)7 complex. 
Image adapted from Sigler et al. (1998). The overall structure and dimensions of GroEL 
(left) and GroEL-GroES-(ADP)7 (right) are shown. The upper panels show the outer 
views while the lower panels show the cavity of the models cut in half through the 
vertical plane.  
 
In eukaryotes, Hsp60 can be found in the chloroplast of plants and mitochondrion 
and cytosol (T-complex polypeptide-1) of mammalian species. While the yeast 
and chloroplast Hsp60 exist and function as tetradecamers, mitochondrial Hsp60 
can exist in solution in a dynamic equilibrium between monomers, heptamers and 
tetradecamers (Levy-Rimler et al. 2002). Mitochondrial Hsp60 forms 
tetradecamers in the presence of ATP while it dissociates into monomers at very 
low concentrations (Levy-Rimler et al. 2001). The cytosolic Hsp60 Hsp60 forms 
heterooligomeric ring structures and assists folding of cytoskeletal proteins such 
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as actin and tubulin (Llorca et al. 2000). 
Hsp60, like most mitochondrial proteins, is a nuclear-encoded protein that carries 
an N-terminal presequence that, upon translocation into the organelle, is cleaved 
off (Wiedemann et al. 2004).  
Recently, the occurrence of extra-mitochondrial Hsp60 has been documented. 
Hsp60 has been found on the cell surface and extracellularly such as human 
circulation (Chapter  1.3.3). Hsp60 in such a localisation has an immunoregulatory 
property and the possibility of cross-reactivity to microbial Hsp60 has been 
implied (Chapter 1.3.4). The localization and function of extra-mitochondrial 
Hsp60 will be discussed in detail in later sections. Because Hsp60 has different 
functions depending on its localization, it is known as a moonlighting protein 
(Shamaei-Tousi et al. 2007a). 
 
1.3.2 Regulation of HSPs 
Heat shock proteins can make up to 5-10% of the total protein content in healthy 
growing conditions, but the synthesis of these proteins can be induced up to 15% 
of total protein content by stresses that induce protein unfolding, misfolding, 
aggregation, or a flux of newly synthesized non-native proteins (Pockley 2003). 
The inducible HSP is regulated by heat shock factors (HSFs), which are 
transcription factors that are normally negatively regulated but activate upon 
stress. In contrast to yeast and fruit fly where only one HSF was identified, several 
members of the HSF family exist for vertebrates and plants, suggesting 
diversification and specialization of these HSFs.  
Although sharing 40% structural homology, HSF 1 functions in response to stress 
stimuli whereas HSF2 activates under early embryonic development, 
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differentiation and is activated by inhibition of ubiquitin-dependent proteasome 
(Pirkkala et al. 2001). Activation of HSF1 begins from oligomerisation from the 
inert monomer to an active trimer, which regains DNA binding activity and 
undergoes stress-induced serine phosphorylation and nuclear localization. 
Subsequently, HSF1 binds to the heat shock element (HSE) located upstream of 
heat shock responsive genes which results in HSP gene transcription. Several 
HSF1-binding proteins have been implied in HSF1 inactivation. For example, 
Hsp70 has been shown to play a role in HSF1 deactivation in several experiments, 
whereas the formation of a heterocomplex involving Hsp90 was shown to 
modulate different steps of the HSF1 activation-deactivation pathway. In addition, 
an 8.5 kDa nuclear protein termed heat shock factor binding protein 1 (HSBP1) 
was also found to hinder oligomerisation of HSF1. The mechanisms to repress 
DNA binding by HSF1 suggest the cell‟s need for tight transcription regulation 
and thereby maintaining protein homeostasis. 
HSF3 is an avian-specific HSF and, like HSF1, it is a stress-responsive 
transcription factor, namely heat response. Activation of HSF3 requires the 
oligomerisation from dimeric to nuclear trimeric structure that acts as a 
transactivator (Pirkkala et al. 2001).  
HSF4 is the most recently discovered mammalian HSF which is restricted to 
certain tissues. HSF4 was shown to have properties of a transcription repressor 
but it is still unclear whether it is a stress-responsive factor.  
Even though HSFs demonstrate differentiated functions, as supported by the fact 
that neither HSF2 nor any other HSF is able to functionally substitute for HSF1, 
HSFs have been proposed to have overlapping roles depending on different 
stimuli. Furthermore, there also exists the possibility that HSFs could cooperate in 
order to regulate expression of their target genes, as shown by the maximal heat 
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protection by avian HSF1 and 3.  
 
1.3.3 Hsp60 “New” Locations 
In addition to its mitochondrial location, increasing reports suggest the existence 
of Hsp60 on the cell membrane and the extracellular space. This is consistent 
across prokaryotic and eukaryotic cells, and under both normal and stress 
conditions.  
 
1.3.3.1 Surface Hsp60 Expression 
Using immunogold cryothin-section EM and immunofluorescence, it was found 
that 16% of the labeled GroEL proteins in the E. coli cell were located in the 
membrane fraction under normal conditions. Furthermore, the density of 
gold-bound GroEL was higher in the membrane region than in the cytosol 
(Newman & Crooke 2000). Other membrane associated Hsp60 in prokaryotic 
cells have been documented and reviewed by Horvath et al. (2008).  
In a study by Solty and Gupta (1996) using immunogold electron microscopy on 
various mammalian cell lines, 80 - 85% of the Hsp60 was localised in the 
mitochondrial matrix whereas the remainder was seen at extramitochondrial sites. 
These sites included the foci of the endoplasmic reticulum, on the cell membrane 
and other unidentified vesicles. The group further confirmed the cell membrane 
localisation by biotin labeling of the plasma membrane proteins and followed by 
immunoprecipitation and Western blots.  
A more recent work by Pfister et al. (2005) also detected the occurrence of surface 
Hsp60 in HUVECs. Confocal laser scanning microscopy (CLSM) revealed that 
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there was no production of Hsp60 on the surface of unstressed cells but after 42°C 
treatment for 30 min (and recovered for 6 h) a significant portion (10.9 ± 3.6%) of 
cells had exposed Hsp60 on the surface, comparable to the 9.5% detected by flow 
cytometry. The number of cells that had surface expressed Hsp60 also increased 
from 1.1% to 9.5% followed by heat stress.  
 
1.3.3.2 Extracellular Hsp60 Expression 
It has been established in recent years that Hsp60 can be found in extracellular 
space and in the circulatory system. Hsp60 has also been detected in the culture 
media followed by stress as measured by enzyme-linked immunosorbant assay 
(ELISA) (Liao et al. 2000). Circulating HSP levels are decreased in aging and 
increased in a number of pathological conditions such as hypertension, 
atherosclerosis and post-trauma or surgery (reviewed by Tsan & Gao 2004; 
Bangen et al. 2007).  
For example, in a study on plasma levels of Hsp60 involving 860 healthy men 
(457) and women (304), 46.9% of the subjects had Hsp60 levels below 1 ng/mL 
(detection limit of ELISA), 26.5% were between 1 and 1,000 ng/mL, and 26.6% 
were above 1,000 ng/mL. Molecular analyses showed that the circulating Hsp60 
was the full-length protein lacking the N-terminal presequence, indicating that the 
circulating Hsp60 originated in the mitochondria of unknown cell types 
(Shamaei-Tousi et al. 2007b). 
 
1.3.3.3 Secretion Pathway 
There is evidence suggesting the involvement of exosomes and/or lipid raft in the 
release of Hsp60 (Gupta & Knowlton 2006), however, regardless of the 
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mechanism, it is believed that Hsp60 is actively secreted rather than by necrosis. 
 
1.3.4 Hsp60 “New” Function 
In addition to their intracellular chaperone roles, HSPs serve as regulators of the 
immune system when expressed on the surface or secreted into the circulation. 
Several studies have shown effects of Hsp60 on the innate and adaptive immune 
systems. Microbial heat shock proteins are known activators of the innate immune 
response (see Table  1.6) and have been shown to elicit potent antigen-specific 
immunity (adaptive immune response).  
Earlier studies revealed that recombinant human HSPs can elicit several immune 
responses through the conserved toll-like receptor (TLR) family. The resulting 
activation of downstream signaling pathway (Toll/IL-1 receptor pathway led to 
activation of NF-κB) and cytokine release patterns shared striking similarity with 
that of bacterial LPS and therefore it was determined that these data were due to 
endotoxin contamination. To overcome this problem, HSPs were purified from 
eukaryotic hosts and several control measures were introduced, such as limulus 
amebocyte lysate (LAL) assay to measure endotoxin levels, treating of HSP with 
polymyxin B which binds LPS, heat denaturation of HSP, and mice defective for 
the recognition of LPS.  
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Table  1.6 – Activation of innate immune cells by microbial heat shock proteins. Adapted 
from Wallin et al (2002). 
Heat shock protein Cell type Effect 
M. leprae Hsp65 Monocytes (THP-1) Production of TNF-α, IL-6 and IL-8 
M. tuberculosis Hsp60 Monocytes (THP-1) CD14-dependent production of TNF-α and 
IL-1β 
M. bovi Hsp65 Monocyte-derived 
macrophages 
Production of TNF-α and IL-1β 
L. pneumophila 
Hsp60, E. coli 
GroEL, M. Leprae 
Hsp65, and M. bovis 
Hsp65 
Peritoneal 
macrophages 
Induction of transcription of TNF-α, IL-1α, 
IL-1β, IL-6 and GM-CSF mRNA, and 
increase in supernatant IL-1 bioactivity 
Mycobacterial Hsp65 Peritoneal 
macrophages 
Production of TNF-α, IL-6 and reactive 
nitrogen intermediates 
L. pneumophila Hsp60 Macrophages PKC- and cell-surface-receptor-dependent 
production of IL-1 
L. pnemophila Hsp60 
and M. bovis Hsp65 
Macrophages Production of IL-12 
Recombinant M. bovis 
Hsp65 
HUVECs Increased adhesiveness to monocytes and 
granulocytes, and up-regulation of E-selectin, 
VCAM-1 and ICAM-1 expression 
E. coli GroES, GroEL 
and DNAk 
Monocytes Production of TNF-α, IL-6 and GM-CSF 
HUVECs Production of IL-6 and GM-CSF, and 
up-regulation of E-selectin, ICAM-1 and 
VCAM-1 expression 
Recombinant 
chlamydial Hsp60 
Vascular 
endothelium and 
macrophages  
Up-regulation of expression of adhesion 
molecules, production of IL-6 and activation 
of NF-κB 
Recombinant 
chlamydial Hsp60 
Macrophages and 
dendritic cells 
Activation of the Toll/IL-1 signaling pathway 
Abbreviations (in alphabetical order): GM-CSF, granulocyte-macrophage 
colony-stimulating factor; ICAM-1, intracellular adhesion molecule 1; IL, interleukin; L. 
pneumophila, Legionella pneumophila; M. bovis, Mycobacterium bovis; M. leprae, 
Mycobacterium leprae; M. tuberculosis, Mycobacterium tuberculosis; NF-κB, nuclear 
factor κB; TNF-α, tumor necrosis factor α; VCAM-1, vascular cell adhesion molecule 1. 
 
33 
Later studies using endotoxin-free HSPs have demonstrated their immune 
stimulatory and modulatory roles in three ways: (1) HSPs bind antigenic peptides 
and mediate major histocompatibility class (MHC) I presentation, (2) they act as 
endogenous danger signals under cell stress and tissue damage, and (3) HSPs bind 
to pathogen-associated molecular pattern (PAMP) molecules and induce signaling 
through pattern recognition receptors (PRR) (Osterloh & Breloer 2008). 
 
1.3.4.1 HSPs are Carriers of Antigenic Peptides 
Cytosolic HSPs such as Hsp70, Hsp90 and gp96 play important roles in antigen 
presentation, cross-presentation, and tumor immunity (reviewed in Tsan & Gao 
2004). The HSP/peptide complex is internalized by antigen presenting cells 
(APCs) via CD91-mediated endocytosis, leading to MHC I presentation and the 
induction of cytotoxic T lymphocytes (CTL). This has significant implications in 
development of vaccines and therapeutics for cancer and infectious diseases. 
However, Hsp60 has not been implicated in binding antigenic peptides and 
therefore will not be discussed in this review. 
 
1.3.4.2 Hsp60 as an Danger Signal 
Two theories have been proposed relating to immune regulation – the Expanded 
Self-Nonself (SNS) theory and the Danger model. The former was proposed by 
Janeway which states that immune response depends on the discrimination 
between “infectious nonself” and “noninfectious self” by APCs (Janeway 1992). 
Antigen presenting cells possess an array of PRRs specific for conserved 
molecules on pathogens (e.g. bacteria), also known as PAMP. Upon PAMP/PRR 
association, APCs become activated by producing costimulatory signals and 
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present foreign antigens to T cells. Toll like receptors are known PRRs and the 
family consists of 10 members (TLR1-10) (Takeda & Akira 2004). This theory 
falls short, however, in describing events such as transplantation, tumors and 
autoimmunity, as Matzinger pointed out (1998). 
The Danger model states that regardless of the „foreign-ness‟ of a substance, what 
really matters in the end is whether it causes damage or not (Matzinger 1998). If 
there is no damage done, the cells and their environment continue to function well 
despite the presence of the substance. However, if the cell dies of necrosis or 
becomes stressed or damaged, an immune response is initiated. Namely, the 
Danger model responds to endogenous signals that originate from stressed or 
injured cells. Such signals can be classified into two categories: pre-packaged and 
inducible.  
Heat shock proteins are good candidate as inducible danger signals as they are 
up-regulated by several stressful conditions and, as discussed in Chapter  1.3.3, 
can be expressed on the cell surface or actively secreted. HSPs such as Hsp60, 
Hsp70, Hsp90 and gp96 from a variety of preparations have been shown to be 
potent activator of the innate immune system, inducing the production of 
cytokines such as TNFα, IL-1, IL-6, IL-12 and the release of NO by monocytes, 
macrophages, and APCs (reviewed by Tsan & Gao 2004). They have also been 
shown to induce the maturation of APCs as demonstrated by the up-regulation of 
MHC class I and II molecules.  
Although it is still under debate whether human Hsp60 is still able to induce the 
above responses without presence of endotoxin co-stimulation, there is evidence 
of a role for Hsp60 in modulating the innate immune response. Osterloh and 
collegues (2004; 2007) demonstrated the ability of Hsp60 to modulate immune 
cell functions by using transgenic cell lines expressing Hsp60 on the cell surface. 
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Surface Hsp60 was shown to induce the maturation of murine APCs and the 
expression of interferon α (IFNα) in these cells. This signaling pathway was found 
to be important for enhanced T cell activation and is distinct to those induced by 
LPS (Osterloh et al. 2007). As Tsan and Gao (2004) pointed out, these 
cytokine-like effects of HSP differ from their molecular chaperone function in that 
they require no peptide binding, no ATP hydrolysis, no cofactors, and no protein 
complex assembly.  
 
1.3.4.3 Modulation of PAMP-Signaling by Hsp60 
Accumulating evidence points to that HSPs are able to bind PAMP molecules and 
in turn modulate PAMP-induced stimulation. Human and murine Hsp60 expressed 
on the cell surface of eukaryotic cells were shown to bind 
3
H-labeled LPS. This 
binding was not only specific, saturable, but also able to be competed by 
unlabeled LPS (Habich et al. 2005). The identification of a LPS binding region on 
the Hsp60 further support a role of Hsp60 as LPS-binding protein (Habich et al. 
2005).  
What happens when Hsp60 binds to LPS? Indeed, HSPs have been shown to 
associate with PRR. Extracellular Hsp60 was shown to bind to macrophages and 
dendritic cells (DCs) in distinct areas that colocalises with CD14 (Osterloh et al. 
2007).  
While it is clear now that highly purified Hsp60 and Hsp70 do not induce the 
release of pro-inflammatory cytokines such as TNFα (Bausinger et al. 2002; Gao 
& Tsan 2003), heat shock protein binding to PAMP was shown to have a 
synergistic effect on inflammatory stimulation. The addition of recombinant 
Hsp60 and Hsp70 was shown to enhance LPS-induced TNFα release in 
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macrophages (Zheng et al. 2004). Similar data were seen by Bangen et al. (2007) 
where pre-incubation of LPS with Hsp60 and Hsp70 caused a dose-dependent 
increase in TNFα secretion by peripheral blood-derived mononuclear cells 
(PBMC). After pre-incubation with LPS, murine cell surface Hsp60 enhanced 
LPS-induced IL-12p40 production in peritoneal macrophages and IFNγ release T 
cells in a synergistic manner (Osterloh et al. 2007).  
Together these data indicate Hsp60‟s role as a multifaceted modulator of the 
innate immune system and have potential influences on the adaptive immune 
responses. Heat shock protein 60 not only acts as an intercellular danger signal but 
also serves as sensors for hazardous signals, providing effective recognition of 
PAMPs such as LPS and increase the efficiency of immune responses. 
Furthermore, HSPs‟ cytokine effects have been proposed to contribute to the 
pathogenesis of autoimmune diseases and chronic inflammation (Tsan & Gao 
2004). 
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1.3.5 Receptor and Signaling Pathway for Hsp60 
The search for the Hsp60 receptors continues to be a controversial topic due to (1) 
possibility of endotoxin contamination even after several control method, and (2) 
the LPS-binding nature of Hsp60. The heated debate centered on whether it shared 
the same receptors for LPS, namely CD14 and TLR4. Heat shock protein 70 have 
been shown to bind to various receptors such as CD14, TLR4, LOX-1, CD40 and 
CCR5 (Binder et al. 2004), it was proposed that either Hsp60 may also be 
promiscuous in receptor binding or that some of these receptors were mistakenly 
identified (Henderson & Mesher 2007). Nevertheless, some evidence of Hsp60 
receptors and signaling are presented here. 
The binding of Hsp60 to different cell types such as macrophage and EC have 
been shown. Using flow cytometry, Alexa Fluor 488 labelled human Hsp60 was 
shown to bind to macrophages in a specific ligand-receptor manner at 
submicromolar concentrations (Habich et al. 2002). This binding was saturable 
and could be competed only with unlabelled Hsp60, not with unrelated control 
proteins. The binding was further confirmed with confocal microscopy and with 
EC and DC (Habich et al. 2002). Furthermore, the binding of human Hsp60 to 
macrophages could not be competed by Hsp60 of hamster or bacterial origins, 
suggesting heterogeneity of receptors for Hsp60 (Habich et al. 2003). 
Using human CD14-transfected astrocytoma cells (which normally lacks response 
to LPS) and Chinese hamster overy (CHO) cells, Kol and colleagues (2000) 
discovered that CD14 was necessary but not sufficient for responsiveness to 
human Hsp60. TLRs have been described as components of the CD14 signaling 
complex and TLR4, in particular, has been described as a co-receptor for LPS 
(Triantafilou & Triantafilou 2002). The group also showed that Hsp60, like LPS, 
induced activation of p38 mitogen-activated protein kinase (MAPK) in PBMC, 
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which resulted in activation of NF-κB leading to the release of IL-6. Limulus 
amebocyte lysate assay and heat sensitivity of Hsp60 were used as control. 
In a study by Vabulas et al (2001), chlamydial and human Hsp60 were shown to 
induce the stress-activated protein kinases c-Jun N-terminal kinases 1/2 (JNK1/2) 
and p38, the MAPK ERK1/2 and the I-κB kinase (IKK) in murine macrophages. 
This activation was mediated by TLR2 and TLR4 as cells defective of these 
receptors displayed impaired responses. In addition, activation of the pathway was 
compromised when cells were treated with an inhibitor known to disrupt 
endocytosis. The preparations of chlamydial and human Hsp60 contained less 
than 0.1 pg/μg protein as determined by LAL assay.  
More recently experiments using genetically engineered eukaryotic cells 
expressing Hsp60 on the cell membrane revealed that the signaling is independent 
of TLR4 and that previous data were due to PAMP-associated TLR signaling 
(Osterloh et al. 2008). In the endotoxin-free environment Hsp60 did not result in 
expression of cytokines such as IL-6, IL-12 and TNFα, but up-regulated IFNα 
expression in APC, which was required for T cell activation. 
Membrane-associated Hsp60 also enhanced IFNγ release in TLR4-mutant APC in 
T cell co-stimulation and this effect was not seen after LPS administration. 
Using a completely different approach in a search for Hsp60 receptors, Henderson 
and Mesher (2007) ran murine whole cell lysate through a column immobilized 
with Mycobacterium tuberculosis Cpn60.1 and the bound fraction was analysed 
by peptide mass fingerprinting. BiP, an Hsp70 in the endoplasmic reticulum 
lumen, VCAM-1 precursor, and polycomb protein Suz 12 were the three 
best-matched candidate for Cpn60.1. Interestingly, the hypothesized receptors, 
CD14 or TLR4, were not identified in this study, possibly due to a detection limit 
of the method or it could indicate previously described receptors were faulty. 
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Hsp70 has been proposed to act synergistically with Hsp60 (Alard et al. 2009), 
making it a likely candidate receptor. 
 
1.3.6 Hsp60 and Diseases 
1.3.6.1 Hsp60 in T2D 
In a study by Aguilar-Zavala and colleagues (2008) TNFα, Hsp60 and other 
markers for chronic disease were measured in patients (n = 151) who < 1 year and 
> 5 years since T2D diagnosis. It was found that Hsp60 associated negatively with 
years since diagnosis and positively with glucose levels. Elevated Hsp60 may be a 
result of psychological and physical damage caused by T2D. This indicates Hsp60 
may be a marker of pathological disorder at the early phase of T2D, similarly to 
the finding that Hsp60 also is associated with early CVD (Pockley et al. 2000). 
The induction of auto-antibodies might explain the decline of Hsp60 in later 
phases (Hoppichler et al. 1996). Elevated Hsp60 may also arise from 
hyperglycaemia-induced tissue damage as indicated by its positive correlation 
with glucose levels. 
Plasma Hsp60 was also measured in 855 T1D and T2D patients by Shamaei-Tousi 
and colleagues (2006). There was a significantly higher proportion of patients 
with CVD and MI had detectable circulating Hsp60 compared with those without. 
This result was in agreement with the proposal that release of Hsp60 into 
circulation is an early risk factor in atherosclerosis (Pockley et al. 2000; Xu et al. 
2000).  
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1.3.6.2 Hsp60 and atherosclerosis 
Since T2D is regarded a CVD risk equivalent, this section will look at how Hsp60 
is associated with the pathogenesis and progression of CVD.  
Several studies have shown that Hsp60 is a powerful immunogen and 
immunomodulator in experimental models of arthritis, diabetes (type 1) and 
atheroscelerosis (Shamaei-Tousi et al. 2007a). With respect to atherogenesis, 
Wick et al. (2004) have generated experimental data to support the hypothesis that 
it is driven by cross-reactive immunity to bacterial Hsp60 proteins. In addition, 
there is increasing data supporting that members of HSP60 are inducers and 
mediators of vascular disease. First, Hsp60 is present in the serum of normal 
individuals (Pockley et al. 1999) and serum Hsp60 levels correlate with the 
presence of early atherosclerosis (Pockley et al. 2000; Xu et al. 2000). Several 
atherosclerosis risk factors (hyperlipidemia, diabetes, smoking, and hypertension) 
have been identified to cause induction of Hsp expression in vascular smooth 
muscle cells (Liao et al. 2000). Shear stress, such as during raised blood pressure, 
has been shown to induce Hsp60 expression in cultured human endothelial cells 
(Hochleitner et al. 2000). Another major contributor to the atherosclerotic plaque 
is foam cells which have accumulated oxidized LDL. Given that in vitro exposure 
to oxidized LDL induces Hsp60 expression by monocytic cell lines, it is likely 
that foam cells in the early atherosclerotic lesion express Hsps (reviewed by 
Pockley 2002).  
During early vascular inflammation, enhanced expression of cytokines such as 
IL-6, VCAM-1 and MCP-1 are often observed. Therefore, alternatively, heat 
shock protein expression may be secondary to the oxidative stress induced by the 
resulting infiltrating leukocytes (Pockley 2002).  
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Once expressed extracellularly, Hsps have the potential to induce the nonspecific 
innate immune system and promote the adaptive immune system (Chapter  1.3.4). 
Indeed, raised levels of anti-HSP antibodies have also been associated with the 
presence and progression of vascular disease. Levels of antibodies to human 
Hsp60 are increased in peripheral vascular disease (Wright et al. 2000) and 
elevated levels of mycobacterial Hsp65 are also documented in various CVDs. 
The existence of such antibodies sparked arguments in relation to vascular injury 
and the pathogenesis of atherosclerosis. Some suggest that self-HSP antibodies 
have direct pro-inflammatory role in autoimmune disease while others have 
shown the presence of immunoregulatory T cells that can differentiate self and 
non-self Hsp60s and exert different outcomes (reviewed by Pockley 2002). 
Since microbial Hsp60s are known potent immunogens involved in the 
pathogenesis of infectious diseases, it is plausible that they were present 
concomitantly under atherosclerotic-driving conditions. Chlamydial Hsp60 
frequently colocalises with human Hsp60 in macrophages of atherosclerotic 
plaques (reviewed by Pockley 2002; Tsan & Gao 2004). Given the Th1 
pro-inflammatory properties of bacterial Hsp60, the coexisting Hsp60 might be 
driving regulatory T cells to produce antibodies and shifts to a Th2-type cytokine 
response (Pockley 2002). 
 
In summary, intracellular Hsp60 can be induced under cellular stresses to fulfill 
cytoprotective functions. The discovery of surface-expressed and circulating 
Hsp60 opened up a new field of research detailing their immune-regulatory roles. 
Human Hsp60 was shown to modulate APC function in a way distinct to LPS 
induction. Furthermore, Hsp60 has the ability to bind to LPS and enhance its 
signals. The immune-stimulatory effects of Hsp60, possibly due to cross-reactivity 
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to microbial Hsp, have been implicated in the development of atherosclerosis. 
T2D is a high risk factor for CVDs and therefore the presence of Hsp60 in T2D 
patients not only is a marker for psychological and physiological stresses but also 
a marker for early atherosclerosis. 
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1.4 Aims and objectives 
Many studies have focused on the effects of metformin on cells of hepatic origin 
but data on monocytic cells are lacking. Circulatory monocytes are key players in 
innate immunity and aberrant expression of surface proteins on monocytes have 
been observed in T2D patients. Further, metformin has been shown to inhibit 
complex 1 of the mitochondrial respiratory chain. We therefore propose that 
metformin may cause a mitochondrial specific stress response through the 
modulation of Hsp60 expression. If Hsp60 was expressed on the surface of the 
stressed monocytic cells it may have immunoregulatory importance.  
In this study, the cytoxicity of metformin will first be investigated in the human 
acute monocytic leukemia THP-1 cell line using different assays. The mRNA and 
protein expression of Hsp60 in metformin-treated THP-1 cells will next be 
determined. Surface expression of Hsp60 has been detected in various cell lines 
previously and here we will investigate whether metformin treatment will result in 
the same.  
Lastly, metformin has been said to have protective effects on CVD risks in T2D 
patients. Since monocyte attachment to ECs and subsequent differentiation into 
macrophages are critical steps in developing atherosclerosis, the effect of 
metformin on PMA-stimulated macrophage formation in vitro will be studied 
here. 
Overall this study aims to gain better understanding of metformin‟s 
pharmaceutical effects on monocytic cells through the studies of (1) its cytotoxic 
effects, (2) mitochondrial stress protein expression, and (3) monocyte-macrophage 
differentiation marker expression.  
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2 Materials and Methods 
2.1 Cell culture and Cytoxicity Assays 
The human acute monocytic leukemia THP-1 cell line was purchased from the 
American Tissue Culture Collection (No. TIB-202). The cells were grown in 
THP-1 media containing RPMI Media 1640 (Gibco) supplemented with 10% fetal 
bovine serum (FBS), 1 mM pyruvate and 1X penicillin/streptomycin. Cells were 
grown at 37°C, 5% CO2 in a humidified incubator (standard incubation 
conditions). Cells were passage every 7 days by centrifugation (Megafuge 1.0) at 
400 rcf approximately and re-suspended with pre-warmed fresh THP-1 media. All 
experiments were carried out using near-confluent cells which have been passaged 
2 days prior to the experiments. 
 
2.1.1 LDH Assay 
Lactate dehydrogenase (LDH) is a cytosolic enzyme which is only released into 
the media by necrotic cells. The Promega CytoTox96 NonRadioactive 
Cytotoxicity Assay kit was used to determine LDH content. Following the 
manufacturer‟s methods, each duplicated sample were treated identically until the 
end of cell culture where one was spun at 400 rcf for 5 min at RT to collect 
supernatant and the other one used as the maximum control. A correct volume of 
10X lysis solution was added to the maximum control and the cells returned to 
standard incubation conditions for 30 min. The cell lysate were centrifuged at 
2,000 rcf for 5 min at 4°C to pellet cell debris. The supernatant of both samples 
were stored in -20°C until further analysis. 
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To reconstitute assay substrate, the substrate vial and buffer were warmed to RT 
and 12 mL of buffer was added to dissolve the substrate. The reconstituted 
substrate was kept at RT until time of assay. On the day of the assay, a positive 
sample was prepared by diluting the LDH Positive 1:1000 in PBS. In a 96-well 
plate, 50 μL of reconstituted substrate was added to 50 μL of positive sample, 
media blank, and sample supernatant in triplicates and incubated at RT for 30 min 
in the dark. The assay was ended by the addition of 100 μL Stop Solution and air 
bubbles removed before measuring the absorbance at 490 nm using a Model 680 
Microplate Reader (Bio-Rad).  
To obtain the percentage of LDH content relative to the maximum control, the 
data was first averaged and then subtracted with the media blank reading. 
Maximum control was multiplied by 1.1 to account for the diluting factor and then 
the sample was normalised to the maximum control (Equation 2.1). The final data 
was presented as a percentage and can be interpreted as the percentage of dead 
cells present in the original cell culture, assuming that each dead cell released an 
equal amount of LDH content. 
 
 
Equation  2.1 – Calculating relative cytoxicity. 
  
Experimental LDH release (OD490) 
Maximum LDH release (OD490) 
% Cytoxicity = 
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2.1.2 MTT Assay 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] is a 
tetrazolium dye which, when reduced by cellular dehydrogenases, forms blue 
crystals intracellularly. The crystals can then be dissolved and quantitated using a 
spectrophotometer. The Sigma MTT Based In vitro Toxicology Assay Kit was 
used with a few adaptations from the manufacturer‟s manual. MTT was dissolved 
in THP-1 media and pre-warmed to 37˚C. A standard curve with varying cell 
density was first carried out to determine cell density to be used. On a 96-well 
plate, 100 µL of THP-1 cells at 10
5
 cells/mL were serially diluted and seeded in 
quadruplicate. A triplicate of blank media was also plated. Followed by an 
overnight rest, one set of serially diluted cells were taken to assess cell density by 
trypan blue (Sigma) exclusion. Ten microlitre of MTT was then added to each 
well and incubated at standard incubation conditions for 1-2 h or until blue 
crystals can be seen under the microscope. Solubilisation solution (100 µL) was 
added to each well and trituration done to help dissolve the crystals. The 
absorbance was read at 570 nm and the background read at 655 nm. After 
subtracting 655 nm readings from 570 nm, blank was subtracted to construct a 
standard curve. The region of cell density with linear increase of absorbance was 
determined for experimental cells. 
 
Equation  2.2 – Calculating corrected MTT absorbance. 
  
Absorbance (corrected) = (Sample OD570 – 655 nm) – (Blank OD570 – 655 nm) 
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Experimental samples were assayed the same way, with 10 µL of MTT per 100 µL 
cell suspension, followed by the addition of 100 µL Solubilization Solution. After 
reading absorbance at 570 and 655 nm the data were calculated as Equation  2.2. 
Experimental values were then normalized to Ctrl and number of cells and 
expressed as a percentage of mitochondrial dehydrogenase activity (Equation  2.3), 
since dehydrogenases are mainly localized in the mitochondria. 
 
 
 
Equation  2.3 – Calculating mitochondrial dehydrogenase activity.  
Mito. dehydrogenase activity (%) = 
Experimental sample absorbance (corrected) 
Ctrl sample absorbance (corrected) 
÷ no. of cells × 100% 
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2.2 Quantification of Hsp60 Expression 
2.2.1 Hsp60 mRNA Expression 
To quantify the Hsp60 mRNA expression in the THP-1 cells, total RNA was 
extracted and reverse transcribed into cDNA. Any DNA contaminant was 
removed by DNase I treatment and semi-quantitative PCR was carried out. These 
methods are described below. 
 
2.2.1.1 RNA extraction 
Total RNA was extracted using TRIzol (Invitrogen) according to the 
manufacturer‟s protocol. Cells were pelleted at 400 rcf for 5 min and supernatant 
discarded. 500 µL TRIzol was used to lyse cells and incubated at RT for 15 min or 
alternatively stored at -80°C. Chloroform (100 µL) was then added to each tube 
and tubes shaken vigorously for 10-15 sec. The mixture was incubated at RT for 3 
min before centrifugation at 12,000 rcf for 15 min at 4°C. The aqueous layer was 
carefully transferred to a new tube and mixed with an equal volume of 
isopropanol. Next, the mixture was incubated at RT for 10 min and centrifuged at 
12,000 rcf for 10 min at 4°C. The supernatant was discarded and the RNA pellet 
washed with 500 µL 75% ethanol in DEPC water. After another centrifugation at 
7,500 rcf for 5 min at 4°C to pellet RNA, the supernatant again discarded and the 
ethanol allowed to completely evaporate. The RNA pellet was re-suspended in 30 
µL TE buffer (Promega) and kept on ice. Quantification of RNA was done with a 
Nanodrop ND-1000 spectrophotometer (Nanodrop). Samples with a 260 to 280 
nm ratio of 1.8-2.1 were considered having good RNA purity. RNA integrity was 
assessed by running the samples on a non-denaturing 1% agarose gel in TBE 
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buffer. Briefly, 1 µg RNA was heated in 65°C for 10 min and immediately placed 
on ice before loading on to the gel. Samples showing discernable 28s and 18s 
rRNA bands in a ratio of 2:1 were considered as having good integrity.  
 
2.2.1.2 DNase I Treatment 
RNA samples were treated with amplification grade DNase I (Roche) before 
cDNA synthesis to remove any contaminating genomic DNA. RNA (1 µg) was 
made up to 8 µL with PCR water and was then mixed with 1 µL 10X reaction 
buffer and 1 µL DNase I. The mixture was incubated at RT for 15 min before the 
addition of 1 µL 25 mM EDTA. Next, a 10 min incubation at 65°C was carried 
out to inactivate the DNase I enzyme, the samples were cooled on ice for at least 1 
min before proceeding to cDNA synthesis. 
 
2.2.1.3 cDNA Synthesis 
cDNA template was synthesized using the Roche Two-Step RT-PCR kit following 
the manufacturer‟s protocol. One microlitre of oligo dT12-18 primer was added to 
the DNase I-treated RNA samples and was incubated at 65°C for 10 min to 
remove secondary structures. A reaction mixture containing 1X RT buffer, 1 U 
RNase inhibitor, 1 mM dNTP, and 1 U reverse transcriptase per reaction was 
made up to a volume of 20 μL with PCR water and mixed gently. The samples 
were incubated at 55°C for 30 min and the reaction terminated at 85°C for 5 min. 
cDNA samples were stored at -20°C. 
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2.2.1.4 Semi-Quantitative PCR 
PCR amplification was carried out using Fast Start Taq Polymerase (Roche). Each 
PCR reaction contained 1 µL cDNA, 1X PCR buffer (MgCl2), 0.2 mM dNTP, 0.1 
µM forward and reverse primers (Invitrogen) (sequences in Table 2.2), 0.2 µL Fast 
Start Taq Polymerase and the volume was made up to 25 µL with PCR water. 
Each PCR run included a negative control containing 1 µL PCR water instead of 
cDNA. The thermocycling conditions for hsp60 and gapdh (the house keeping 
gene) are described in Table 2.1 below.  
Table  2.1. Thermocycling conditions for hsp60 and gapdh PCR. 
Product  Denaturation Annealing Extention  
hsp60 
Initial 
denaturation 
at 95°C for 4 
min 
95°C 
1 min 
55°C 
1 min 
72°C 
1 min 
Final 
extension at 
72°C for 10 
min 
gapdh 
95°C 
1 min 
60°C 
1 min 
72°C 
1 min 
 
The number of cycles that lied within the linear amplification range was used to 
quantitate the gene of interest by normalising to gapdh expression levels. The 
PCR products were run, along with a DNA ladder, on a 1% agarose gel stained 
with EtBr and buffered in 1X TAE. The gels were run at 80 V for approximately 
40 min and visualised by exposing to UV light and an image acquired by a 
MiniBIS Pro Illuminator controlled by GelCapture software (both by DNR 
Bio-Imaging Systems). The intensity of the bands was analysed using the Gel 
Quant software (DNR Bio-Imaging Systems). 
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Table  2.2 – Primer sequences for hsp60 and gapdh PCR. 
Product Sequences Product size 
hsp60 
Forward: TTC GAT GCA TTC CAG CTT G 
Reverse: TTG GGC TTC CTG TCA CAG TT 
439 bp 
gapdh 
Forward: ACC ACA GTC CAT GCC ATC AC 
Reverse: TCC ACC ACC CTG TTG CTG TA 
451 bp 
 
2.2.2 Hsp60 Protein Expression 
2.2.2.1 Protein Extraction 
Total protein was isolated using the TENT buffer containing 50 mM Tris (pH 7.5), 
250 mM NaCl, 5 mM EDTA (pH 8.0), 1% Triton X-100 and freshly supplemented 
with 0.4 mM phenylmethylsulfonyl fluoride as protease inhibitor.  
THP-1 cells treatment with metformin (0 – 500 µM) were pelleted at 400 rcf for 5 
min and ruptured with 100 µL TENT buffer by vortexing. Followed by 30 min 
incubation at 4°C, samples were spun at 10,000 rcf for 5 min at 4°C to pellet cell 
debris. The supernatant was transferred to a new tube and stored at -20°C until 
further analysis. 
 
2.2.2.2 Protein Estimation 
Protein concentration was estimated using the BCA Protein Assay Kit (Pierce) 
following the manufacturer‟s protocol. A working reagent (WR) was made up 
containing 50 parts of reagent A with 1 part reagent B prior to the assay. A 
standard curve comprised of known concentrations of serially diluted bovine 
serum albumin (BSA) (Pierce) in phosphate buffered saline (PBS) was assayed 
along with samples with unknown concentrations. Twenty-five microlitre of each 
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standard and unknown was transferred onto a 96-well plate in duplicates followed 
by the addition of 200 µL WR to each well. The content was mixed briefly on a 
plate shaker before incubating at 37°C for 30 min. The plate was read at 560 nm 
using the Microplate Reader and the concentration of samples calculated from the 
standard curve. 
 
2.2.2.3 Protein Separation and Transfer 
Gel Preparation 
Total protein was separated on a discontinuous gel (0.76mm). The 10 % 
separating polyacrylamide gel was prepared by mixing the following reagents: 4.1 
mL distilled water, 2.5 mL 1.5 M Tris (pH 8.8), 100 µL 10% SDS, 3.3 mL 
acylamide-bis stock (Bio-Rad). Immediately before casting, 50 µL 10 % 
ammonium persulphate (APS, prepared fresh) (Bio-Rad) and 10 µL TEMED 
(Bio-Rad) were added in a fume hood and the mixture applied between the plates. 
A layer of 70 % ethanol was immediately overlaid gently. The separating gel was 
allowed to polymerise for 1 h.  
The stacking gel was prepared by adding 6.1 mL distilled water, 2.5 mL 0.5 M 
Tris (pH 6.8), 100 µL 10 % SDS, 1.3 mL acylamide-bis stock (4%), 50 µL 10 % 
APS and 10 µL TEMED. Once the separating gel was set, the ethanol was poured 
off and was washed with the stacking gel mixture. The stacking gel was casted on 
top of the separating gel and the comb gently inserted and allow to it to 
polymerise for 45 min. The gel was assembled in a Mini-Protean 3 Cell gel tank 
(Bio-Rad) buffered with 1X electrode buffer.  
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Sample Preparation 
Each sample containing 15 µg total protein was made up to a volume of 20 µL 
with protein loading buffer. The samples were denatured in boiling water bath for 
5 min before loaded in the wells. Five microlitre of protein Kaleidoscope ladder 
(Bio-Rad) and a Hsp60 standard (250 ng) were also loaded alongside the samples. 
The gel was electrophoresed at 200V for 40 min or until the dye front reached the 
bottom. 
Semi-Dry Transfer 
Semi-dry transfer was carried out using a 3-buffer system containing a cathode 
buffer and anode I & II buffers (see Common solutions in Chapter 2.5). The gel 
was removed from the glass plates and trimmed to the relevant area and 
equilibrated in cathode buffer for 15 min. In parallel, a sheet of 0.45 µm 
nitrocellulose membrane (Bio-Rad) was cut to the same size of the gel and gently 
placed in anode buffer II to equilibrate for 5 min. Six pieces of extra thick filter 
paper (Bio-Rad) was cut slightly bigger than the membrane; three of which 
soaked in cathode buffer, two in anode buffer I and one piece in anode buffer II. 
The transfer sandwich was assembled as in Figure 2.1 and air bubbles removed by 
rolling action over the top of the stack. Once the cathode plate was pressed down, 
the transfer cell (Bio-Rad) was run at 15V for 90 min. 
 
 
 
Figure  2.1 – The assembly of a semi-dry transfer sandwich. (Image adapted from 
Millipore Immobilon-P user guide) 
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After transfer, the membrane was rinsed in ddH20 briefly before stained with 
Ponceau S for 1 min to assess loading consistency. The stain was then washed 
away with ddH20 before western blotting. 
 
2.2.2.4 Western Blotting 
The membrane was blocked in 10 % skim milk in TBST overnight at 4°C. The 
following day, the membrane was incubated in polyclonal rabbit anti-Hsp60 
(Stressgen SPA-805) 1:5,000 in 5 % skim milk in TBST for 1 h at RT on a rotary 
shaker. After 3 X 5 min washes in TBST, the membrane was then incubated in 
peroxidase conjugated goat anti-rabbit IgG (Sigma) 1:1,000 in 5 % skim milk in 
TBST for 1 h at RT. Another 3 X 5 min washes in TBST was carried out and the 
membrane transferred onto a glass plate. The membrane was incubated with 
SuperSignal West Pico Chemiluminescent Substrate (Pierce) for 5 min and 
covered with a piece of clear plastic sheet. The membrane was visualized by the 
LAS-1000 Plus Gel Documentation System (Fujifilm) and the intensity of the 
bands was analysed using the Gel Quant software. 
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2.3 Differentiating THP-1 Cells 
2.3.1 Cell Culture 
Phorbol 12-myristate 13-acetate (PMA) (Sigma) was used to stimulate 
differentiation of monocyte cells into macrophages. On a 24-well plate, near 
confluent THP-1 cells cultured in metformin-containing media (0, 100, 250, 500 
µM) were treated with 50 nM PMA for 2-3 days or until cells show macrophage 
characteristics under the microscope. 
 
2.3.2 CD14 mRNA Expression 
Total RNA extraction and subsequent procedures were similar to Chapter 2.2.1 
with a few changes, as described below. 
 
2.3.2.1 RNA Extraction 
Cells showing macrophage characteristics were harvested and total RNA extracted 
using TRIzol. This procedure differed slightly to Chapter 2.2.1.1 in that most cells 
were adherent. The media was transferred to eppendorf tubes and spun at 400 rcf 
for 5 min and the pellet containing suspended cells was lysed in 250 µL Trizol. 
Meanwhile, the attached macrophages were lysed using 250 µL Trizol. The two 
portions were combined and the RNA extraction carried out as described in 
Chapter 2.2.1.1. DNase I treatment and cDNA synthesis were carried out the same 
way as Chapter 2.2.1.3 and 2.2.1.4, respectively. 
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2.3.2.2 Semi-Quantitative PCR of CD14 
The effect of metformin on the differentiation of THP-1 cells was determined by 
the expression of cd14 mRNA in the extracted total RNA samples. DNase I 
treatment and cDNA synthesis were carried out as described in Chapter 2.2.1.2 
and 2.2.1.3, respectively.  
Semi-quantitative PCR was carried out as described in Chapter 2.2.1.4 and the 
thermocycling conditions and primer sequences for cd14 PCR are indicated in 
Table 2.3 and 2.4, respectively. 
 
Table  2.3 – Thermocycling conditions for cd14 and gapdh PCR. 
Product  Denaturation Annealing Extention  
cd14 
Initial 
denaturation 
at 95°C for 4 
min 
95°C 
1 min 
52°C 
30 sec 
72°C 
30 sec 
Final 
extension at 
72°C for 10 
min 
gapdh 
95°C 
1 min 
60°C 
1 min 
72°C 
1 min 
 
Table  2.4 – Primer sequences for cd14 PCR. 
Product Sequences Product size 
cd14 
Forward: CTG CAA CTT CTC CGA ACC TC 
Reverse: CCA GTA GCT GAG CAG GAA CC 
215 bp 
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2.4 Surface Expression of Hsp60 
2.4.1 Cell Preparation 
For staining to be carried out on poly-L-lysine pre-coated microscopic slides, 
THP-1 cells were first pelleted at 400 rcf for 5 min and re-suspended in 
pre-warmed PBS to a cell density of 5 x 10
4
 cells/mL. Next, 150 µL of cells was 
spun onto slides using a Shandon Cytospin 4 Cytocentrifuge (Thermo Scientific) 
at 600 rpm (41 rcf) for 3 min. This speed and time combination was optimised to 
maintain cell integrity during centrifugation (as tested by trypan blue staining) and 
to allow cells to remain adhered to the slides during the washing steps. The area of 
the monolayer of cells was marked using a Dako Pen (Dako) before placing the 
slide into the fixative. For live cell staining, cells were also spun onto the slides 
using the cytospin using the above settings at the end of the experiments. 
 
2.4.2 Cell Fixation 
After cells were spun onto slides using a cytospin, several fixatives were trialed 
(Table 2.5) to select the one which will not permeabilise the cells.  
The cells were washed in 3 X 5 min PBS before staining with 500 nM propidium 
iodide (PI) (AppliChem) for 5 min in the dark. After another 3 X 5 min PBS wash 
the slides were air-dried briefly and fixed with Dako fluorescent mounting agent 
(Dako) and stored at 4°C wrapped in foil. 
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Table  2.5 – Fixatives trialed for surface preservation. 
Fixative Content Conditions 
Methanol:Acetone (1:1) Freshly made HPLC grade methanol and 
acetone  
RT for 15 min 
Methanol, ice cold Fresh HPLC grade methanol pre chilled 
at -20°C 
-20°C for 10 
min 
4% Paraformaldehyde in 
PBS 
In the fumehood, measure, dissolve 2 g 
of paraformaldehyde (PFA) powder in 
40 mL PBS. Add 2 drops 10 M NaOH. 
Stir on 65°C plate until clear. Adjust pH 
to 7.4 and bring volume to 50 mL. Filter 
through a 0.2 µm filter. Store at 4°C. 
RT for 10 min 
1% Paraformaldehyde in 
PBS 
Mix 1 part 4% PFA with 3 parts PBS. RT for 10 min 
4% Formaldehyde in PBS Dilute 37% formaldehyde solution in 
PBS to 4% formaldehyde. 
RT for 10 min 
1% Formaldehyde in PBS  Mix 1 part 4% formaldehyde in 3 parts 
PBS. 
RT for 10 min 
2% Glutaraldehye Dilute the 50% glutaraldehyde stock 
solution to 2% with PBS 
RT for 10 min 
 
2.4.3 Hsp60 Immunocytochemistry 
In live cell immunocytochemistry (ICC), THP-1 cell media was replaced with 
pre-warming media containing rabbit anti-Hsp60 antibody (1:200) and incubated 
at 37˚C for 1 h. A negative control was included which did not have the 
anti-Hsp60 antibody. Following 3 X 5 min washes with pre-warmed PBS, cells 
were incubated in media containing FITC-conjugated anti-rabbit IgG (1:400) 
(Jackson ImmunoResearch) for 1 h. The cells were washed three times in PBS, 
stained with PI for 5 min and spun onto slides using a cytospin. The cells were 
washed in PBS for 3 times and then mounted with Dako mounting agent. 
Alternatively, cells were spun onto slides by a cytospin and then ICC was carried 
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out after the cells were fixed with 1% PFA.  
 
2.4.4 MitoSOX Red Staining 
MitoSOX Red (Invitrogen) specifically targets mitochondria in live cells where it 
gets oxidised by superoxide and exhibits its red fluorescence. Following the 
manufacturer‟s manual, MitoSOX Red was dissolved in DMSO to make a 1 mM 
stock and a 0.5 μM working solution was made in pre-warmed THP-1 media. Live 
THP-1 cells were gently smeared onto a slide and air dried for 5 min before a 
generous drop of MitoSOX working solution was applied over the cells and the 
slide was incubated at 37˚C for 30 min. After three 5 min washes in PBS the cells 
were fixed in 1% PFA at RT for 10 min. Another three 5 min washes were done 
and the cells were counterstained in 300 nM DAPI in PBS for 5 min. The slide 
was washed and mounted with the Dako mounting agent. 
 
The microscopic slides in this section were viewed under a Nikon Eclipse TS100 
inverted microscope with a UV block and appropriate filters. Images were taken 
with a Nikon CoolPix 4500 digital camera. Alternatively, an Olympus FV1000 
laser scanning confocal microscope (LSCM) controlled by the Olympus FluoView 
software (ver1.6a) was used. 
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2.5 Media, Reagents & Common Solutions Preparation 
Name Composition 
THP-1 media 1 mL 100 mM sodium pyruvate 
1 mL 100X penicillin/streptomycin 
10 mL FBS 
Bring volume to 100 mL with RPMI 1640 medium then filter 
through a 0.22 μm filter. Store at 4˚C. 
 
Metformin (100 mM) 212 mg metformin (HCl) 
Dissolve in 10 mL ddH2O and filter through a 0.22 μm filter. 
Store at 4˚C in 1 mL aliquots. 
 
Metformin (25 mM) Mix 1 part 100 mM metformin and 3 part sterile ddH2O. Store at 
4˚C in 1 mL aliquots.  
 
0.1 % DEPC water 1 mL DEPC 
1 L ddH2O 
Stir over night and then autoclave. 
 
0.5 M EDTA 14.61g EDTA 
Dissolve in 80 mL ddH2O, adjust to pH 8 then bring to 100 mL. 
 
10x TBE buffer 54g Tris 
27.5 boric acid 
20 mL 0.5M EDTA 
Dissolve in 900 mL ddH2O then bring volume to 1L. 
 
50x TAE buffer 141g Tris 
28.55 mL glacial acetic acid 
50 mL of 0.5 M EDTA 
Dissolve in 300 mL ddH2O , pH should be 8.5 then bring 
volume to 500 mL. 
 
Phosphate buffered 
saline (PBS) 
8g NaCl (137 mM) 
0.2g KCl (2.7 mM) 
1.44g Na2HPO4 (4.0 mM) 
0.24g KH2PO4 (1.7 mM) 
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Dissolve in 800 mL ddH2O and adjust to pH 7, bring to 1L. 
 
1.5M Tris-HCl pH 8.8 90.83g Tris 
Dissolve in 400 mL ddH2O, adjust to pH 8.8 and bring to 500 
mL. 
 
0.5M Tris-HCl pH 6.8 15.14g Tris 
Dissolve in 200 mL ddH2O, adjust to pH 6.8 and bring to 250 
mL. 
 
10% SDS 25g SDS 
Make up to 250 mL with ddH2O water. 
 
5x Electrode buffer 15g Tris (124 mM) 
72g glycine (959 mM) 
50 mL of 10% SDS (0.5%) 
Made up to 1L with ddH2O. 
 
Protein loading buffer 3 mL 10% SDS 
1 mL 1M Tris pH6.8 
0.2 mL 2% bromophenol blue 
4 mL glycerol 
0.8 mL ddH2O 
Mix well and store in 1 mL aliquots at -20˚C. 
Add β-mercaptoethanol (5%) fresh on the day. 
 
Gel fixative/destain 400 mL methanol (40%) 
100 mL acetic acid (10%) 
500 mL of ddH2O 
 
Commassie Blue stain 0.5g Brilliant Blue R-250 (0.1%) 
Dissolve in 500 mL of fixative/destain and filter through #1 
filter paper 
 
Cathod buffer 0.303g Tris 
0.3g glycine 
10 mL methanol 
Dissolve in 80 mL ddH2O, adjust to pH 9.4 and bring to 100 mL. 
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Anode buffer I 3.63g Tris 
10 mL methanol 
Dissolve in 80 mL ddH2O, adjust to pH 10.4 and bring to 100 
mL. 
 
Anode buffer II 0.303g Tris 
10 mL methanol 
Dossolve in 80 mL ddH2O, adjust to pH 10.4 and bring to 100 
mL. 
 
10x Tris buffered 
saline 
(TBS) 
12.10g Tris (0.1M) 
87.66g NaCl (1.5M) 
Dissolve in 800 mL ddH2O, adjust to pH 7.7 and bring to 1 L. 
 
Ponceau S Add in the order: 
10 mL MQ water 
0.3 mL glacial acetic acid 
33mg Ponceau S 
Bring to 30 mL with MQ water and store at RT. 
 
TBS-Tween (TBST) 100 mL 10x TBS 
0.5 mL Tween20 (0.05%) 
Make up to 1 L with ddH2O. 
 
TENT buffer 1.51g Tris (50 mM) 
10.96g NaCl (150 mM) 
0.37g EDTA (5 mM) 
0.75 mL TritonX-100 (0.25%) 
Dissolve in 200 mL ddH2O, adjust to pH 7.4 and bring to 250 
mL. Supplement with 0.4 mM phenylmethylsulfonyl fluoride 
fresh. 
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2.6 Statistical Analysis 
All statistical analysis in this study was carried out using Microsoft Excel. Data 
were averaged when appropriate and standard error of the mean (S.E.M.) was 
calculated using Equation  2.4 in Excel.  
 
 
Equation  2.4 – Calculating standard error of the mean in Excel. 
 
A two-tailed student‟s t-test was carried out to determine the significance of the 
data. The accepted level of significance was p < 0.05, which was denoted as “*”, 
whereas p < 0.01 was denoted as “#” throughout this study. 
 
STDEV (A1:A2) / SQRT (COUNT (A1:A2)) 
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3 Effects of Metformin on THP-1 Cell 
Culture 
3.1 Introduction 
T2D is associated with a chronic low-level state inflammation and therefore 
patients are at a high risk for developing CVD. Metformin is a widely prescribed 
anti-hyperglycaemic drug and it has been shown to inhibit the complex 1 of the 
mitochondrial respiratory chain (Chapter  1.2.4.1). Although its cytotoxicity has 
been characterized in hepatocytes and HepG2 cells (Dykens et al. 2008), there is a 
lack of such study on human monocytic cells, the cells that can elicit innate 
immune responses and play important roles in the pathogenesis of atherosclerosis 
(Chapter  1.1.4). Therefore, THP-1 human monocyte cells were chosen as an in 
vitro model to study the effects of metformin on the immune system.  
The plasma concentration of metformin has been documented at 10 – 100 μM in 
humans and mice and it could reach 10 mM in the intestine (Wilcock & Bailey 
1994). Various researchers have used metformin concentrations from the range of 
10 μM to up to 30 mM in cell cultures but due to the differences in the cell type 
and nature of experiment, the first task of this project was to test the toxicity of 
metformin on intact THP-1 cells. A range of metformin concentration was chosen 
and (0, 10-500 μM, and 1, 10 mM) supplemented to cells growing at near 
confluent stage. First of all, cell growth was monitored every 48 h by Trypan blue 
exclusion assay, then LDH assay was used to measure the cytoxicity of metformin. 
Lastly, MTT assay was carried out to measure cell viability and indirectly measure 
mitochondrial dehydrogenase activity (Marshall et al. 1995). 
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3.2 Methods 
3.2.1 Cell Culture 
Metformin stock at 25 mM and 100 mM was prepared as in Chapter 2.5. A uridine 
stock at 20 mM was also prepared in the same way. THP-1 cells at the exponential 
growth phase were seeded at a density of 22,000 cells/mL onto a 24-well plate 
containing 1.5 mL media with 0, 10, 100, 250, 500 µM and 1 and 10 mM 
metformin in duplicates. Another 24-well plate contained the same metformin 
concentrations but the media was supplemented with 200 µM uridine. Uridine is 
required for cellular pyrimidine biosynthesis when the mitochondrial electron 
transport system is inactive (Martinus et al. 1993). The plates were then placed 
back in standard incubation conditions and the cell density estimated by the trypan 
blue exclusion method every 48 h. 
 
3.2.2 LDH Assay 
Lactose dehydrogenase is an intracellular enzyme which will only be released 
after cell death. The measure of LDH in the cell supernatant is therefore a way to 
assess cytoxicity.  
Near confluent THP-1 cells treated with metformin (0 – 500 µM) were seeded 
onto a 24-well plate in 1 mL duplicates and incubated in standard incubation 
conditions. After 48 h, samples were prepared as described in Chapter  2.1.1. 
Briefly, one set of cells was pelleted to collect supernatant while the other set of 
cells (maximum control) was lysed with 100 µL Lysis Solution and supernatant 
collected. After the assay, Stop Solution was added and absorbance measured at 
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490 nm. The data were calculated according to Equation 2.1 and presented as a 
percentage of the corresponding maximum control. 
 
3.2.3 MTT Assay 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay is 
commonly accepted as a measure of cell proliferation and/or viability and is based 
on the activity of intracellular oxidoreductase enzymes, where NADH is 
responsible for most MTT reduction (Berridge et al. 2005). Since most 
oxidoreductases are localized in the mitochondrial respiratory chain, the assay 
here is also an indirect measure of mitochondrial respiration. The assay was 
carried out following the supplier‟s manual and with the methods described in 
Chapter  2.1.2. 
On a 96-well plate THP-1 cells at 12,000 cell/mL were serially diluted and plated 
to construct a standard curve for MTT assay. It was determined that cell density 
below 6,000 per well was suitable for the assay. Cells treated with metformin (0, 
100, 250, 500 µM) was seeded at around 4,000 cells per well in quintuplicate and 
rest overnight. Duplicated wells of each treatment group were taken to assess cell 
density and 10 µL MTT added to the remaining triplicated wells. After 30 min 
incubation (or until blue crystals were seen) at 37°C, 100 µL Solubilization 
Solution was added and proceed as described above. The data was subtracted with 
655 nm readings and corresponding blanks then normalised to the cell densities 
noted at the beginning of the assay. 
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3.3 Results 
3.3.1 Cell Growth 
As shown in Figure  3.1a, Control (Ctrl) cells containing no metformin had a 
doubling time of 48 hrs as usual and the 10 μM group had comparable if not faster 
doubling time. Cells treated with 100 and 250 μM metformin showed a slight 
reduced growth rate compared with Ctrl whereas the 500 μM and 1 mM groups 
had 73.73% and 48.12% of the Ctrl cell number, respectively, at the end of the 
culture period. 10 mM metformin was cytotoxic as cells were unable to multiply 
and were no longer viable after 2 days. 
In parallel, cells were treated the same way except 5 mM pyruvate and 0.2 mM 
uridine (hereon abbreviated as “Rescue” or “R”) were added to the media as 
supplements for cells with compromised mitochondrial respiratory chain. The 
cells were treated for the same length of time and cell numbers noted (Figure  3.1b). 
With Rescue, Ctrl, 10, and 100 μM groups had similar doubling time whereas 250 
and 500 μM showed concentration-dependent decrease in growth rate. The 
cytotoxic effect of 10 mM metformin was seen as early as 2 days and the effect 
was beginning to show at 96 h for the 1 mM group. 
 
68 
0
20
40
60
80
100
120
140
0 50 100 150
C
e
lls
 (
1
0
3 /
m
L)
Hours
Ctrl
10 μM
100 μM
250 μM
500 μM
1 mM
10 mM
0
20
40
60
80
100
120
140
0 50 100 150
C
e
lls
 (
1
0
3 /
m
L)
Hours
Ctrl + R
10 μM + R
100 μM + R
250 μM + R
500 μM + R
1 mM + R
10 mM + R
a)               b) 
 
 
 
 
 
 
 
 
 
 
Figure  3.1 – Cell growth in metformin. a) Without Rescue. b) With Rescue (5 mM pyruvate + 0.2 mM uridine). Error bars showing S.E.M.
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To compare cells in the absence and presence of Rescue, the number of cells at 
each time point was normalised to the number of Ctrl cells. The slopes were then 
taken from the graph plotting against the percentage of surviving cells versus time 
(not shown) and presented in Figure  3.2, which indicates the rate of growth 
inhibition for each treatment. 10 μM metformin appeared to increase cell 
proliferation or prevent cell death regardless of Rescue presence; 100 μM showed 
differentiated effects where the Rescue relieved the inhibition seen without 
Rescue. At metformin concentrations 250 μM and above, cells showed a 
dose-dependent increase in growth inhibition. Figure  3.2 also indicates that, 
regardless of the presence of Rescue, 1 mM metformin had approximately 50% 
growth rate of Ctrl and that 10 mM metformin is highly toxic to cells.  
Due to metformin‟s cytotoxic effect at 10 mM, this dose was excluded from 
experiments from here on. 
 
 
 
 
 
 
 
 
Figure  3.2 – Rate of cell death in metformin relatively to Ctrl. 
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3.3.2 LDH Assay 
Lactate dehydrogenase is an intracellular enzyme that is only released into the 
media upon cell death, thus this assay was used to determine the cytoxicity of 
metformin on THP-1 cells.  
After 72 h in culture, the percentage of LDH content relative to corresponding 
maximum control samples were calculated. Assuming that every death cell 
released equal amount of LDH, the percentage of LDH content was interpreted as 
the percentage of lysed cell as shown in Figure  3.3. The control sample had 45.04 
± 0.99% lysed cells, and was not significantly different to 100 and 250 µM groups, 
which had 43.97 ± 1.40% and 45.42 ± 0.46% lysed cells, respectively. Treatment 
of 500 µM and 1 mM metformin resulted in a significantly reduced (p < 0.05) 
percentage of lysed cells compared with Ctrl, giving 39.72 ± 0.44% and 33.60 ± 
1.33% lysed cells, respectively. 
 
Figure  3.3 – Percentage of lysed cells in the presence of metformin. Bar graph showing 
means ± S.E.M. * = p < 0.05. 
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3.3.3 MTT Assay 
A standard curve was constructed by serially diluted THP-1 cells and MTT assay 
was carried out to ensure MTT forzaman deposit is proportional to cell number. 
As Figure 3.4 indicates, cell number beyond 6,000 per well began leveling off in 
crystal formation and therefore seeding culture for experimental assay were 
approximately 4,000 cells per well.  
The indirect measurement of mitochondrial dehydrogenase activity in the 
presence of metformin showed that there is a slight increase at 100 µM (117.67%). 
At 250 and 500 µM there is a decreasing trend, 95.35 and 59.07%, respectively, 
indicating inhibited mitochondrial respiration (Figure 3.5). The difference in the 
amount of blue deposit between Control and 500 µM metformin can be seen 
through light microscopy in Figure  3.6d. 
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Figure  3.4 – Standard curve for MTT assay. Cell number up to around 4,000 per well 
showed linear increase in absorbance. 
 
 
 
 
 
 
 
 
Figure  3.5 – Mitochondrial dehydrogenase activity in the presence of metformin. Bar 
graph showing the mean ± S.E.M of triplicated wells. # = P < 0.01. 
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a)          b) 
 
 
 
 
 
c)          d) 
 
 
 
 
 
Figure  3.6 –Blue formazan deposits intracellularly after 30 min incubation. a-d) show crystal formation in Ctrl, 100, 250, and 500 µM groups, respectively. 
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3.4 Discussion 
The objective of this study was to assess the cytotoxicity of metformin on THP-1 
monocyte cells. Three methods were used: trypan blue exclusion, LDH assay and 
MTT assay. While all of these are measures of cell viability, MTT assay is 
commonly used as an indirect measurement of mitochondrial respiration 
(Marshall et al. 1995). 
It was reviewed in Chapter  1.2.1 that plasma metformin levels ranges from 10 – 
100 μM and in the intestine it could reach 10 mM in diabetic mouse 
(Wiernsperger 1999). In this experiment, THP-1 cells were incubated with a wide 
range of metformin concentrations and it was shown that within plasma levels of 
metformin, THP-1 cells grew similarly to the Ctrl. It was clear that 10 mM 
metformin was highly cytotoxic as THP-1 cells could not maintain viable for 
periods longer than 48 h (Figure  3.1a & b).  
Knowing metformin is a complex 1 inhibitor, cells were supplemented with 5 mM 
pyruvate and 0.2 mM uridine („Rescue‟ or R) in an effort to restore cell viability at 
high drug dosages. These two supplements have been shown to allow the growth 
of cells completely lacking the mitochondrial respiratory system (Martinus et al. 
1993). The reduction of pyruvate to lactate provides a pathway for the 
re-oxidation of excess NADH generated during glycolysis, whereas uridine is 
required for cellular pyrimidine biosynthesis when the mitochondrial electron 
transport system (ETS) is inactive. This Rescue did not have significant effects on 
cell growth as shown in Figure  3.2 probably because (1) lactate buildup reduces 
cell growth: under metformin inhibition, cells accelerate glycolysis to compensate 
for reduced ATP production via oxidative phosphorylation. The resulting lactate 
from glycolysis normally serves as substrate for gluconeogenesis in the liver and 
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therefore in this cell culture system lactate could not be completely oxidized, 
leading to a buildup in cell culture. (2) Accelerated glycolysis at high metformin 
concentrations could lead to fast turnover rate for glucose and therefore substrate 
depletion is another factor. This could explain the lack of influence of Rescue. (3) 
Metformin also affects other pathways involved in cell growth. For example, 
metformin is a known activator of AMPK, a cellular energy sensor. When 
activated, cells switch on catabolic pathways that generate ATP while switching 
off biosynthetic pathways and other processes that consume ATP, such as protein 
synthesis (Hardie et al. 2006). 
The LDH assay showed that compared with Ctrl (45.0%), 500 μM and 1 mM 
groups had significantly reduced (p < 0.05) cell lysis, at 39.7% and 33.6%, 
respectively. This indicated that inhibited growth in 500 μM and 1 mM metformin 
was not to due to cell death but possibly due to metformin‟s inhibitory effects on 
mitochondrial respiration. The evidence for this will be discussed later. 
Interestingly, reduced cell death by metformin has been observed by other studies 
(Guigas et al. 2004). Metformin was shown to prevent cell death induced by a 
glutathione-oxidising agent (t-BH) through delaying the mitochondrial PTP 
opening, and therefore prevent cell death. The authors postulated that the ability 
of metformin to inhibit PTP opening may help prevent deleterious effects caused 
by hyperglycaemia, adding to metformin‟s favourable effects. Similarly, 
metformin also prevented high glucose-induced cell death in HMEC-1. The data 
here is consistent with metformin‟s cytoprotective effect.  
In support of metformin being a mild complex 1 inhibitory, there were two 
observations documented in this study. Firstly, it was noted that after a few days 
the colour of media became yellow as metformin concentration increased, most 
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likely due to the buildup of lactic acid during glycolysis, as described above. The 
second evidence for complex 1 inhibition came from MTT assay as it indicated a 
significant 40.93% inhibition in mitochondrial dehydrogenases at 500 μM 
metformin. Although it has been argued that reduction of MTT can also occur in 
cellular compartments other than mitochondria such as on the plasma membrane 
or in the cytosol, it was suggested that the contribution of mitochondria to the 
reduction decreased over time (Bernas & Dobrucki 2002). Therefore the assay 
was stopped as soon as MTT deposit was clearly seen under the microscope to 
minimize extramitochondrial reduction. Previously, 100 μM metformin was 
shown to exhibit 12.6% of mitochondrial respiration using glutamate and malate 
as substrate in rat hepatoma cells at 24 h (Owen et al. 2000). Another experiment 
showed that 10 mM metformin inhibited 53% of respiration in KB (human 
carcinoma-derived) cells after 30 min (Guigas et al. 2004). The extent of 
mitochondrial inhibition was not as great as the above, possibly due to the 
difference in cell types and the assay used, as MTT assay is not a direct 
measurement of complex 1 activity. This probably explained the lack of inhibition 
of respiration at 100 μM metformin. 
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4 Effects of Metformin on Mitochondria as 
Indicated by Modulation of Hsp60 
4.1 Introduction 
It is now widely known that metformin is a mild but specific inhibitor for complex 
1 of the mitochondrial respiratory chain (Chapter  1.2.4.1) and data presented in 
the previous chapter supports this concept. The aim of this chapter is to assess the 
stress level in metformin treated THP-1 cells by monitoring the expression of 
Hsp60, a mitochondrial stress protein. Accordingly, mRNA and intracellular levels 
of Hsp60 were determined by semi-quantitative PCR and Western blot, 
respectively. 
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4.2 Methods 
4.2.1 Cell Culture 
On two separate 6-well plates, near confluent THP-1 cells were seeded at a 
density of 71,000 cells/mL in 3 mL of media containing 0, 100, 250, and 500 μM 
metformin and kept at standard incubation conditions. At 72 h, approximately 1 
mL (10
5
 cells) of cells from each plate was removed for RNA and protein 
extraction. Pre-warmed media was then added to each well to bring volume back 
to 3 mL. The same process was repeated at 7 and 14 days. 
 
4.2.2 Hsp60 mRNA Quantification 
RNA extraction was carried out as described in Chapter  2.2.1.1 and this was 
followed by DNase I treatment (Chapter  2.2.1.2) and cDNA synthesis 
(Chapter  2.2.1.3). Finally, hsp60 and gapdh PCR was carried out (Chapter  2.2.1.4) 
and the products ran on an agarose gel, visualised and quantitated. The cycle 
number that represented the linear increase region was used to calculate the 
relative hsp60 expression and fold changes.  
 
4.2.3 Protein Extraction 
Protein extraction was carried out as described in Chapter  2.2.2. Briefly, protein 
extracted by TENT buffer was assayed to determine protein concentration 
(Chapter  2.2.2.2). Fifteen microgram of protein was then separated on a 10% 
SDS-PAGE and transferred to a nylon membrane (Chapter  2.2.2.3). Western blot 
was carried out to visualise and quantitate the Hsp60 bands (Chapter  2.2.2.4). 
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4.3 Results 
4.3.1 mRNA levels 
Hsp60 mRNA levels were determined by semi-quantitative PCR and normalised 
to GAPDH expression. After three days incubation of metformin with THP-1 cells, 
there was a statistically significant (P < 0.05) decrease (0.29 ± 0.17 of Ctrl) in 
hsp60 expression at 250 µM. There was a 1.18 ± 0.11 and 3.02 ± 1.39-fold 
increase at 100 and 500 µM, respectively, but this was found to be not significant 
based on the Student‟s t-test (Figure  4.1a).  
At seven days exposure to metformin, hsp60 expression increased dramatically at 
all concentrations compared with Ctrl (Figure  4.1b). Hsp60 mRNA had a 7.27 ± 
0.40, 6.67 ± 0.82, and 9.68 ± 0.23-fold increase in the 100, 250, and 500 µM 
groups, respectively.  
At 14 days, the 500 µM group continued to show a significant increased hsp60 
level (2.66 ± 0.26-fold) (Figure  4.1c). In contrary, the other two groups showed 
decreased levels, at 0.58 ± 0.03 and 0.14 ± 0.00 (p < 0.05) of the Ctrl, 
respectively.  
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Figure  4.1 –Hsp60 mRNA and protein expression in response to metformin. Left panel 
shows the mRNA expression and right panel shows the protein expression. THP-1 cells 
were treated for 3 days (top), 7 days (middle), or 14 days (bottom). Bar graphs represent 
mean ± S.E.M. *= p < 0.05 and # = p < 0.01. 
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Overall, in response to 500 μM exposure hsp60 remained elevated compared to 
Ctrl throughout the experiment with a peak expression at seven days. Significant 
increase in hsp60 was only seen at seven days for 100 and 250 μM groups while 
other times it was mostly unchanged or decreased.  
 
4.3.2 Protein levels 
After total protein was separated on a polyacrylamide gel and transferred to a 
nylon membrane, Ponceau S staining showed the standard Hsp60 band to be at 60 
kDa and that protein loading was even. After Western blot a single band for the 
each sample was seen and the bands appear to be same size as the standard Hsp60 
protein band (data not shown). The bands were quantitated using the Gel Quant 
software and the relative expression to Ctrl was plotted (Figure  4.1d-f). 
 
 
 
 
 
 
Figure  4.2 – Western blots of Hsp60 at 3, 7 and 14 days. Equal loading was confirmed by 
Ponceau S staining. 
  
3 days 
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Hsp60 protein expression follows a similar, but somewhat delayed pattern to 
mRNA expression, with some exceptions. At three days, there was no significant 
change in comparison to Ctrl at all metformin concentrations although there was a 
slight (1.62-fold) increase in Hsp60 at 500 μM metformin. 
At seven days, a dramatic increase was seen at 250 and 500 μM metformin 
resulting in 10.55 and 25.28-fold increase in Hsp60, respectively. In the two 
western blots carried out, the Ctrl band in one was not detectable and therefore 
student t-test could not be done. Nevertheless, the increase in Hsp60 expression 
was obvious as seen in Figure  4.2.  
At 14 days, Hsp60 showed a dose-dependent increase in 100 and 250 μM 
compared with Ctrl, at 7.83- and 15.40-fold, respectively. Again, the Ctrl was not 
detectable in one blot thus statistical analysis was not possible. There was no band 
detected in the 500 μM group. 
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4.4 Discussion 
Up-regulation of the mitochondrial Hsp60 has been used previously as a marker 
for stressors that target mitochondria specifically, such as in ρ˚ cells lacking 
mitochondrial DNA and in COS-7 cells expressing a mutant mitochondrial mutant 
protein (Martinus et al. 1996; Zhao et al. 2002). In this chapter, Hsp60 mRNA and 
protein expressions were measured in THP-1 cells were treated with metformin 
for 3, 7, or 14 days. This experiment is unique in that a monocytic cell line was 
used and the exposure to metformin is relative long term compared to other 
studies.  
The nuclear-encoded Hsp60 transcript showed an up-regulation as early as three 
days at 500 μM and remained elevated throughout the experiment, however the 
100 and 250 μM groups showed only a transient up-regulation which occurred at 
day seven. The up-regulation of hsp60 suggests metformin treatment caused a 
mitochondrial stress response in THP-1 cells possibly due to inhibited oxidative 
respiration. To confirm this correlation, an experiment can be set up in a temporal 
way where mitochondria are isolated for the measurement of oxygen consumption 
and hsp60 expression measured.  
The protein levels of Hsp60 stayed mostly unchanged at day three then a 
corresponding increase in 250 and 500 μM groups was observed at day seven, 
although there was a lack of an increase in Hsp60 at 100 μM. While 100 and 250 
μM groups showed a dose-dependent increase in mRNA levels at 14 days, the 
opposite trend was seen at the protein level. A few possible mechanisms exist for 
this transient mRNA response with marked protein increase: (1) the transcription 
of hsp60 was attenuated by proteins that bind to HSF thereby repressing DNA 
binding. (2) A delayed protein expression is due to a lag in translation from 
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mRNA transcripts. (3) The cells have reduced ability to response to stress due to 
high passage number, which is reflected on hsp60 expression. (4) An increase in 
Hsp60 protein levels does not necessarily require up-regulated transcription. 
In Chapter  1.3.2 it was reviewed that HSFs, the transcription factors governing the 
transcription of HSPs, are normally inactivated by HSF binding proteins. Many of 
these HSF binding proteins are in fact HSPs so that a feedback regulation exists to 
maintain protein homeostasis. Therefore, although metformin-treated cells are 
constantly under mitochondrial stress, the expression of hsp60 is fluctuating by a 
series of activation and deactivation. One way to confirm this is by promoter 
reporter assays. For example, Zhao et al. (2002) transfected COS-7 cells with a 
construct containing chloramphenicol acetyl transferase (CAT) and luciferase 
(LUC) downstream of hsp10 and hsp60 promoter, respectively, which allowed the 
detection if the promoter was activated. 
It was shown in heat shocked monkey Stertoli cells that hsp60 responded after 4 h 
however Hsp60 levels did not increase until 12 h after treatment (Chen et al. 
2008). Similarly, the marked increase in hsp60 at day seven would require time to 
allow for translation and translocation to the mitochondria. Thus, at the time of 
protein isolation, the proteome most likely represented the transcripts hours before 
this. This would probably explain the discrepancy in mRNA and protein levels in 
this experiment. 
The lack of Hsp60 expression can also be explained by the senescence of cells. In 
human diploid fibroblasts (HDFs) it was shown that late passage cells were less 
sensitive to oxidative stress and therefore did not elicit Hsp60-mediated apoptosis 
as early passage cells did (Lee et al. 2008). The senescence-associated marker 
appeared at passage 30 (P30) in HDFs (Lee et al. 2008) and was seen at passage 
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P20 in another study (Ghneim et al. 2003). THP-1 cells used here were at P18-20 
and could potentially be “aged” and had reduced stress response as implicated by 
hsp60 expression. An assay measuring senescence biomarkers such as the 
senescence-associated β-galactosidase (SA-β-gal) can be done to determine this. 
In a study on the role of Hsp60 in apoptosis, it was noted that an accumulation of 
Hsp60 in the cytosol without mitochondrial release and did not seem to result 
from increased mRNA levels in PC3 cells (Chandra et al. 2007). A similar 
scenario where Hsp60 increased without a corresponding mRNA increase was 
also observed in rat kidney cortex cells (Itoh et al. 2002) but the underlying 
mechanisms remain unclear. It is possible that the marked increase in Hsp60 seen 
here resulted in the same fashion as the above. Interestingly, the accumulation of 
Hsp60 without mitochondrial release was associated with an anti-apoptosis 
outcome (Chandra et al. 2007). Further, rotenone, a more potent version of 
metformin, caused cytosolic Hsp60 accumulation without mitochondrial release 
(Chandra et al. 2007). An interesting follow-up experiment would be the 
determination of Hsp60 in cytosolic and mitochondria fractions versus total 
protein to see whether a similar effect to rotenone can be seen. Since metformin 
has been shown to prevent cell death (Chapter  1.2.5 and also Chapter 3), it is 
possible the up-regulated Hsp60 expression plays an anti-apoptotic role. 
It could not be determined from these results whether Hsp60 up-regulation was a 
mitochondrial specific response or a general cellular stress response. LDH assay 
indicated at day 3 the cells were healthy (Chapter 3) but the assay was not carried 
out day seven or 14. The lack of a Hsp60 band in Figure 4.1 (f) was probably due 
to poor maintenance in long term treatment in high metformin causing cell death 
but LDH assay was needed to verify this. In addition, inducible HSPs such as 
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cytosolic Hsp70 and mtHsp70 should be included as indicators of general stress. 
Future work should also include LDH and MTT assays at each time point along 
with stress markers that are not specific to mitochondria. If metformin did induce 
a mitochondrial-specific stress it signifies that a mechanism exists in sensing the 
mitochondrial stress followed by mitochondria-nuclear communication which 
ultimately leads to the activation of target genes.  
The increased levels of total Hsp60 protein in this chapter raised questions as to 
whether these proteins can be expressed on the cell surface, as has been shown 
previously. Surface exposed Hsp60 has important immunological roles (Chapter 
1.3.4) when expressed on the circulatory monocytic cells especially in the diabetic 
context. The identification of surface Hsp60 in metformin-treated THP-1 cells will 
be described in Chapter 6. 
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5 Effects of Metformin on Differentiation of 
THP-1 Cells 
5.1 Introduction 
Type 2 diabetes is accompanied with various pathophysiological conditions that 
put patients at a 2-4 times higher chance of developing CVD (Chapter 1.1.4). 
Although still inconclusive, metformin may have protective effects against CVD 
based on trials, animal models and cell culture studies (Chapter  1.2.6).  
Differentiated THP-1 macrophages have been widely used as an in vitro model of 
human macrophages to study their involvement in inflammation (Tuomisto et al. 
2005; Kang et al. 2009). The aim of this chapter was to determine the response of 
metformin-treated THP-1 cells to PMA. The marker chosen for monocyte 
differentiation was CD14, a surface receptor present on macrophages (Tuomisto et 
al. 2005). The expression of CD14 and Hsp60 mRNA was determined by 
semi-quantitative RT-PCR.  
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5.2 Methods 
5.2.1 Cell Culture 
Near confluent THP-1 cells at 50,000 cells/mL were seeded onto a 24-well plate 
in media containing 0, 100, 250, or 500 μM metformin. The cells were returned to 
standard incubation conditions to rest overnight. The second day, a stock of 10 
μM PMA was diluted in DMSO and added to each plate to make a final PMA 
concentration at 50 nM. After 48 h the cells were harvested as described in 
Chapter 2.2.6. 
 
5.2.2 CD14 and Hsp60 mRNA Quantification 
Total RNA was extracted in TRIzol as described in Chapter 2.3.2.1 which is 
slightly modified from Chapter 2.2.1.1 as cells were no longer in suspension. 
DNase I treatment, reverse transcription and semi-quantitative PCR were carried 
out as described in Chapter 2.2.1.3&4 and 2.3.2.2 and the primer sequences for 
cd14 can be found in Table 2.4. CD14 was chosen as a marker as it is one of the 
ten highly up-regulated genes in PMA-stimulated THP-1 macrophages compared 
to undifferentiated THP-1 monocytes (Tuomisto et al. 2005) and its activation is 
commonly seen in T2D  and may be associated with inflammation (Fogelstrand 
et al. 2004; Cipolletta et al. 2005).  
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5.3 Results 
THP-1 cells treated with metformin were differentiated with PMA and the 
expression of a macrophage marker, cd14, was measured. Already at 19 h, THP-1 
cells have shown characteristic morphology of macrophages such as adhesion and 
spreading (Figure  5.1). Cells were harvested at 48 h by TRIzol and adhesion was 
stable as cells could not be detached by washing. 
At 48 h after PMA addition, cells treated with 100 μM metformin showed a 
significant 1.48-fold increase in cd14 expression compared with Ctrl (Figure  5.2a). 
In contrary, the 500 μM group had significantly decreased cd14 levels, at 
0.23-fold of the Ctrl. The 250 μM group had comparable levels of cd14 to Ctrl. 
The levels of hsp60 were also measured in THP-1 derived macrophages and showed 
significant increases in all metformin concentrations compared with Ctrl, at 2.74, 1.49 
and 2.08-fold, respectively (Figure  5.2b, light shade). Figure  4.1a, the expression of 
hsp60 in undifferentiated THP-1 cells, is also plotted in Figure  5.2b (dark shade). It 
shows that 100 and 250 μM groups had significant elevated hsp60 levels after 
differentiation (p < 0.05 and p < 0.01, respectively). The levels of hsp60 before and 
after differentiation had no significant changes. 
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Figure  5.1 – THP-1 monocytes and THP-1-derived macrophages. Monocytes have 
round-shaped morphology (left) and macrophages adopt elongated morphology with 
clustering and spreading of the cells. 
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Figure  5.2 – Expression of cd14 and hsp60 in metformin-treated THP-1-derived 
macrophages. * = p < 0.05; # = p < 0.01. 
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5.4 Discussion 
Monocyte activation and recruitment and subsequent differentiation into 
macrophages are crucial steps in the development of atherosclerosis as reviewed 
in Chapter  1.1.4. In this chapter, the ability of PMA-stimulated THP-1 
differentiation in the presence of metformin was investigated. Using a specific 
surface receptor, CD14, as a gene marker for differentiation it was found that 
therapeutic concentration of metformin (100 μM) caused a significant 1.48-fold 
increase in cd14 levels at 48 h (Figure  5.2a). At 500 μM metformin, however, cd14 
levels were significantly decreased and the 250 μM group had similar levels of 
cd14 compared with Ctrl. 
Binding of CD14 to LPS is known to initiate intracellular signals which ultimately 
lead to the secretion of pro-inflammatory cytokines. The binding of LPS also 
leads to clustering with other receptors that are involved in atherosclerosis such as 
CD11b, CD18, and scavenger receptor CD36 (Pfeiffer et al. 2001). Therefore the 
data here indicate that THP-1 monocyte cells exposed to metformin at the 
therapeutic range expressed higher levels of cd14 than Ctrl cells, thereby may 
have high chance of promoting pro-inflammatory responses. Stimulation of 
THP-1-derived macrophages with LPS and subsequent measurement of TNFα 
levels in the culture media could be carried out to confirm this. 
In Chapter 3 it was shown that 500 μM metformin markedly reduce cell growth 
rate by reduced respiration. The reduced ability for cells to differentiate, as 
indicated by cd14 expression, likely reflects limited ability for cells to carry out 
energy costing activities. This is supported by the evidence that metformin 
activates the AMPK pathway, leading to inhibition of anabolic pathways 
(Chapter  1.2.4.2).  
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It was stated in a meeting abstract by Mamputu et al. (2002) that metformin was 
shown to reduce differentiation of culture human monocytes into macrophages 
and monocyte adhesion to endothelial cells and that foam cell formation was also 
reduced. Unfortunately the full article was not available so it is unclear which cell 
type, culture conditions and metformin concentration were used. Thus the data in 
this study could not be compared to our study.  
In a trial involving 112 women aged 64 years with T2D, IGT or NGT it was 
shown that T2D group had higher levels of CD14+ monocytes as measured by 
flow cytometry than the latter two groups (Fogelstrand et al. 2004). Further, 
treatment with metformin had no influence on the results (Fogelstrand et al. 2004). 
The discrepancy could be a result of the malignant cell type used in this study and 
also an increase in mRNA expression does not necessary correlate with protein 
expression. The correlation coefficient between the expression of THP-1 derived 
macrophages and human peripheral blood mononuclear (HPBM)-derived 
macrophages range from 0.80 to 0.88 depending on the time-point and stimulation 
used (Tuomisto et al. 2005). The main difference lies in genes related to cell 
proliferation. In a comparison study on gene and protein expression in monocytes 
and monocyte-derived macrophages, it was found that expression changes in 
protein level were smaller than changes at the mRNA level, probably due to 
transcript variants and selective translation (Tuomisto et al. 2005). Therefore, 
future studies should include the measurement of surface CD14 in THP-1 cells (or 
HPBM cells) exposed to metformin using flow cytometry. Other molecules that 
could potentially be involved in development of atherosclerosis, such as Cdk-1 
(transcription factor) and CD36 can also be determined, perhaps in a 
time-dependent manner.  
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In the current study, the expression of hsp60 was also measured and found to be 
up-regulated after differentiation (Figure  5.2b). Transcriptional activation of 
several HSPs, namely the stress-inducible Hsp60, Hsp70, Hsp90 and the 
constitutive Hsc70, have been documented in peritoneal macrophages induced by 
colony stimulating factor (CSF) (Teshima et al. 1996). The transcription of these 
genes coincided with O
2-
 production by macrophages stimulated with PMA 
indicated that HSPs may play a protective role against harmful oxidative damage 
associated with the respiratory burst (Teshima et al. 1996). The maturation of 
macrophages involves up-regulation of several genes and subsequent protein 
synthesis and folding, which further justify the induction of molecular chaperones.  
The up-regulation of hsp60 in the 100 μM group observed in this study could be 
the result of the above reasons. However the elevated levels of hsp60 cannot be 
explained the same way in 250 and 500 μM groups, as THP-1 cells appeared to 
have similar or less ability to differentiate. Whether this was due to elevated 
cellular stress is unclear as the expression of other HSPs was unavailable.  
In summary, THP-1 monocytes treated with a therapeutic concentration of 
metformin had increased differentiation rate as measured by cd14. At high 
metformin (500 μM) cells showed significant reduced differentiation compared 
with Ctrl. Depending on the metformin concentration used, the elevated hsp60 
levels may be a result of (1) an influx of newly synthesized protein due to the 
transition from monocyte to macrophage; (2) increased requirement for 
cytoprotection due to oxidative damage associated with macrophage respiratory 
burst; and/or (3) a cellular stress condition caused by metformin treatment. The 
results here partly contradicted the much acclaimed beneficial effect of metformin 
on CVD however more conclusive data are required.
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6 Optimisation of Surface Hsp60 Detection 
6.1 Introduction 
Surface expressed Hsp60 has been detected in stressed rat aortic endothelial cells 
and human umbilical venous endothelial cells (HUVECs) using 
immunocytochemistry (ICC) (Xu et al. 1994; Pfister et al. 2005). Surface Hsp60 
has also been detected in other cell lines such as Chinese hamster ovary (CHO) 
(Soltys & Gupta 1996), human T-cell lines (Soltys & Gupta 1997) and human 
breast and lung carcinoma cells (Barazi et al. 2002). The aim of this chapter is to 
optimize a method for detection of surface expressed Hsp60 in human monocytic 
THP-1 cells. The expression of Hsp60 on the cell surface under cellular stress, in 
this case metformin, may have important physiological and pathological 
significance in the context of T2D. 
The optimisation involved using different cytospin speeds, fixing with different 
agents, and ICC in live or fixed cells. The results will be discussed in the same 
section in this chapter. 
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6.2 Methods 
To obtain intact cell membrane for surface Hsp60 staining, the cytospin settings 
were first optimised. Next, several fixatives were trialed without the 
permeabilisation step. Alternatively, ICC was carried out in live cells. The 
methods of cytospin, fixation and Hsp60 ICC are described in Chapter 2.4. The 
cells were viewed under an inverted microscope or a confocal microscope. 
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6.3 Results and Discussion 
6.3.1 Cytospin 
THP-1 cells in suspension were spun using a cytospin centrifuge at various speeds 
and duration. The mildest combination to spin cells onto a poly-L-lysine 
pre-coated slide was 600 rpm for 3 min. At a shorter time cells tend to wash off 
during washing steps in ICC. Immediately after cytospin the cells were stained 
with Trypan blue and Figure  6.1 shows that cell viability was > 90%.  
 
Figure  6.1 – Trypan blue staining of cells after cytospin. Cells that have taken up the dark 
blue dye indicates a loss of membrane integrity, hence are dead cells. 
 
6.3.2 Fixatives 
The staining of PI requires permeabilisation of cell membrane, thus skipping this 
step should theoretically allow the staining of only necrotic cells. However this 
was not the case, at least not in THP-1 cells. 
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Figure ‎6.2 – THP-1 cells stained with PI after fixation with different agents. 
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Figure 6.2 (continued) – THP-1 cells stained with PI after fixation with different agents. 
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Of the fixatives used, formaldehyde and PFA at 1% seemed to have allowed the 
least PI staining, indicating good fixing agents (Figure  6.2b,f). Using 
methanol/acetone (1:1), ice cold methanol, 4% aldehydes and 2% glutaraldehyde 
seemed to allow PI to penetrate the membrane and stain the nucleus of most cells 
(Figure  6.2a, c, d, e, g) comparable to permeabilised cells (Figure  6.2h).  
Later it was found that if cells were stained with PI before cytospin and fixation, 
the PI-stained cells co-localised with the cells stained with trypan blue, indicating 
only dead cells took up the dyes (Figure  6.3). A few examples are indicated by the 
arrows below. Thus, Hsp60 ICC and PI were carried out under standard 
incubation conditions prior to fixation. 
 
 
 
 
 
Figure  6.3 – Co-localisation of PI and trypan blue staining. The arrows indicate examples 
of dead cells stained by both trypan blue and PI. 
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6.3.3 Confocal Microscopy and Hsp60 ICC 
The immunostaining with anti-Hsp60 antibody was carried out next and the slides 
were examined by CLSM to gain better resolution and reduce bleaching. The 
anti-Hsp60 antibody has previously been shown in MIN6 cells to co-localise with 
transfected GFP-Hsp60, see Figure  6.4 (Martinus & Johnson unpublished data).  
Figure  6.5 shows the cells stained with PI only, Hsp60 ICC negative (without 
primary antibody), Hsp60 ICC after cells were fixed, Hsp60 ICC in live cells, and 
cells stained with MitoSOX red. The nucleus was stained with either PI or DAPI 
in Figure  6.5. Using transmitted light (TL) all the cells could be seen and this 
gives an overview of cell morphology.  
 
Figure  6.4 – Hsp60 expression in MIN6 cells. From left to right, anti-Hsp60 antibody, 
GFP-Hsp60 and the merger of the two. 
 
Propidium iodide stained most of the cells as shown in Figure  6.5a. Some cells 
have a flattened appearance as shown by the TL image, probably an artifact due to 
centrifugation by cytospin. The intensity of the dye also varied between cells and 
this was commonly seen in all slides. 
The Hsp60 ICC negative in Figure  6.5b shows there was non-specific binding of 
the FITC-conjugated secondary antibody. During ICC there was no additional 
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blocking agent (BSA) but FBS was present at all time in culture media. The use of 
detergent was also avoided in washing butter (PBS) as it is known to cause 
rupture of the cell membrane. The cells which have non-specific binding seem to 
be those that have not taken up PI, indicating that these cells were not necrotic. 
Interestingly, cells stained with PI seemed to have a flattened appearance as 
shown by the TL image, indicating they may have been ruptured or splattered 
during the cytospin procedure. 
Hsp60 ICC was carried out either in live or fixed cells. The videos of the 
sequential z-stack images can be found in the complementary CD at the back 
cover (video 1-3). The collapsed z-stack images are shown in Figure  6.5c & d 
which show that ICC in live and fixed cells have very different staining patterns, 
indicating that the fixative (1% PFA) changed the structure of the antigen in some 
way. This is different to the study by Pfister et al. (2005) who showed that fixation 
(4% PFA or MeOH/acetone) of HUVECs did not alter the distribution of 
„clustered‟ Hsp60 on the surface. In the current study, fixed cells had a uniform 
„cloudy‟ FITC pattern and most cells (90%) have taken up PI (TL image not 
shown). Hsp60 ICC in live cells had distinct FITC „speckles‟ in approximately 
20% of the cells but most cells also had the „cloudy‟ pattern. PI staining had 
varied intensities as mentioned earlier and around 10% of cells had high PI 
intensity. The cells with „speckles‟ had medium PI intensity.  
The „speckles‟ in Figure  6.5d were possible surface expressed Hsp60 as these did 
not resemble the commonly described mitochondrial morphology such as 
„bean-shaped‟, or network-like interconnected tubular structures (Karbowski & 
Youle 2003). Further, surface expressed Hsp60 had been described to have a spot- 
or string-shaped appearance in ECs (Xu et al. 1994), similar to the „speckles‟ seen 
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here. To differentiate from mitochondrial Hsp60 staining, THP-1 cells were 
stained with a mitochondrial specific dye, MitoSOX red, which targets functional 
mitochondria that are producing superoxide. Figure  6.5e shows cells stained with 
MitoSOX red (coloured orange used to distinguish from PI) and counterstained 
with DAPI after cells were fixed. This is a collapsed image of the z-stack and the 
video can also be found in the complementary CD (video 4). Unlike Figure  6.5d, 
these cells had more areas in orange, indicating abundant mitochondria, more or 
less arranged around the nucleus. Some are „bean-shaped‟ but most are also 
„speckled‟ or spotty however a tubular network structure was not seen here.  
Although Figure  6.5d & e (or videos 2 & 3) are different in the arrangement and 
the intensity of the FITC and MitoSOX staining, they still share a similar spotty 
pattern. Thus it cannot be ruled out that the „speckles‟ in Hsp60 ICC are 
intracellular Hsp60. The weak PI staining in these speckled cells also led us to 
question the integrity of the cell membrane and, thus the possibility of 
mitochondrial Hsp60 staining. Furthermore, a study by Pfister and colleagues 
(2005) revealed that the number of cells expressing surface Hsp60 was only 1% in 
unstressed HUVECs and it increased to around 10% in heat-stressed cells. 
Similarly, only a „weak staining‟ was seen in normal aortic ECs as oppose to 
„bright staining‟ in stressed cells (Xu et al. 1994). In healthy THP-1 cells, around 
20% of the cells had notable speckles which may indicate (1) a higher surface 
Hsp60 expression in this particular cell type; (2) cells being under an unknown 
stress, perhaps the additional handling during live cell ICC; (3) better recognition 
of this antibody to surface Hsp60 epitope than antibodies used by other studies; or 
(4) cells being partially leaky, as weak PI staining was seen in all cells, potentially 
allowing mitochondrial Hsp60 staining.  
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a) PI only 
 
 
 
b) Anti-Hsp60 negative 
(live cell) 
 
 
c) Fixed cell ICC 
 
 
 
d) Live cell ICC 
 
 
 
e) MitoSox red (live cell) 
 
 
 
Figure  6.5 – Confocal microscopy of ICC. The description as indicated above. Red = PI; 
green = FITC; blue = DAPI; and orange = mitoSOX red. The scale bars all show 10 μm. 
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In summary, this study showed that THP-1 cells have different Hsp60 ICC pattern 
depending on the sequence of fixation and that ICC in live cells appeared to stain 
surface Hsp60. There is certainly more work to be done to test the reproducibility 
of the current staining method and to find a way to reduce non-specific binding of 
secondary antibody. This could involve adding a blocking agent to the media or 
employing a more stringent washing step. Also, it should be investigated why 
healthy cells took up faint PI. Most importantly, experiments which show directly 
whether metformin treatment has an effect on surface expression of Hsp60 should 
be carried out. An important consideration here is that increased surface Hsp60 
caused by metformin may exacerbate CVD risks in T2D patients who already 
express elevated levels of adhesion molecules in ECs (Fogelstrand et al. 2004; 
Cipolletta et al. 2005; Hartge et al. 2007), and monocyte-EC interaction is the one 
of the key steps in the development of atherosclerosis (Libby 2002; Mestas & Ley 
2008).
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7 Final Summary and Future Directions 
This study looked at several aspects of metformin treatment on human monocytic 
leukemia THP-1 cells. Chapter 3 showed that metformin at the therapeutic 
concentrations of metformin (100 μM) had little effects on cell growth rate, cell 
death and mitochondrial respiration. At a higher concentration (500 μM), however, 
metformin significantly decreased cell growth rate and mitochondrial 
dehydrogenase activity. Ten millimolar metformin was cytotoxic to THP-1 cells 
which raises questions to how valid and relevant it is in those studies that used 10 
mM or even higher concentrations. 
It is now clear that one of metformin‟s molecular targets is the complex 1 of the 
mitochondrial respiratory chain (Owen et al. 2000; Guigas et al. 2004) and results 
from MTT assay supported this. Using Hsp60 as a mitochondrial stress marker, it 
was noted that cells treated with 500 μM metformin had elevated mRNA levels of 
this marker throughout the 2-week experiment, a relatively long term incubation 
compared with other studies. At other concentrations the mRNA levels fluctuated 
but the protein levels increased in a time- and concentration-dependent manner at 
day 7 and day 14. It is unsure whether the increased expression of Hsp60 
represented a mitochondrial-specific response, thus future study should include 
the expression of other HSPs to rule out general cellular stress response. 
The results here also agree with the finding that metformin inhibits cell death 
(Guigas et al. 2004; Detaille et al. 2005), which was seen at 500 μM and 1 mM. 
Interestingly, cytosolic accumulation of Hsp60 has been associated with an 
anti-apoptosis outcome (Chandra et al. 2007). In the diabetic context, metformin 
may have protective effects against glucotoxicity-induced cell death. 
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Recently metformin has received much attention for its potential beneficiary 
effects on CVD outcome in T2D patients. Since monocyte differentiation marks a 
critical step in atherosclerosis the effects of metformin on THP-1 differentiation 
was carried out. It was found that 100 μM metformin resulted in significantly 
higher cd14 expression in PMA-stimulated monocyte differentiation at 72h. CD14 
is a surface receptor for bacterial LPS and it was proposed that through elevated 
cd14 cells may respond to an infection better. Future work should confirm the 
up-regulation of cd14 at other time points as well as identification of the receptor 
protein on the cell surface.  
Finally, the detection of surface expressed Hsp60 was attempted and it seemed, 
for THP-1 cells, Hsp60 ICC should be carried out in live cells. In contrary to 
Pfister et al. (2007), the fixatives tried here either did not maintain membrane 
integrity or changed the antigen structure. ICC in live cells showed „speckles‟ of 
Hsp60 staining which is similar to that described by Xu and colleagues (1994). 
However, the amount of „speckles‟ in healthy cells here appeared to be much 
higher than other studies. Whether this was due to differences in cell type and 
antibody used is unclear. Future work should test the reproducibility of this 
staining procedure and further optimize to reduce non-specific binding and 
cytospin-induced cell rupture. 
Based on the findings in this study, it appeared that THP-1 cells have increased Hsp60 
expression under prolonged metformin exposure, even at a therapeutic dosage. THP-1 
monocytes also had higher expression of cd14 at this dosage with accompanying 
hsp60 increase. The expression of either protein on the cell surface could have 
important roles in immunity as (1) both are known to bind PAMP such as LPS and 
can promote a pro-inflammatory response, and (2) in diabetes, circulatory monocytes 
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can attach to ECs expressing elevated levels of adhesion molecules and become 
lipid-laden foam cells, thus fueling an atherosclerotic event. Future studies should 
focus on these aspects of metformin-induced surface molecules perhaps using a 
co-culture system containing primary cell cultures and observe their interaction with 
ECs.  
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